Auna Q3 net income falls 54% to S/24 million
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Auna S.A. (AUNA) reported third-quarter 2026 revenue of S/1,325 million, up 19% as reported and 10% on an FX-neutral basis. Adjusted EBITDA was S/231 million, flat as reported and down 5% FX-neutral; net income was S/24 million, compared with S/53 million a year earlier. Mexico segment Adjusted EBITDA rose 5% in local currency, while Peru declined 6% and Colombia declined 30%.
For the nine months ended September 30, 2026, operating cash flow rose 62% to S/713 million and free cash flow rose 95% to S/626 million. Net debt was S/3,133 million and leverage was 3.5x at September 30, 2026, compared with 3.6x at September 30, 2025 and December 31, 2025.
Auna reaffirmed full-year 2026 revenue growth guidance of 10% to 14% FX-neutral and capital expenditures of approximately 4% of consolidated revenues. Its Adjusted EBITDA outlook is now broadly stable or slightly down year over year, versus prior guidance of 10% to 14% FX-neutral growth. The Centro Ambulatorio Trecca project entered construction on November 3 after conditions were fulfilled; it is structured as a 20-year concession, with operations currently expected by late 2028.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointRevenue increased 19% as reported in 3Q26, including 10% FX-neutral growth.
- Moderate pointNine-month operating cash flow rose 62% to S/713 million.
- Moderate pointNine-month free cash flow rose 95% to S/626 million.
Negative
- Major point. Forward-looking: it has not happened yet and may not happen.Full-year Adjusted EBITDA outlook shifted from 10% to 14% FX-neutral growth to broadly stable or slightly down year over year.
- Moderate pointThird-quarter net income fell 54% to S/24 million year over year.
- Moderate pointThird-quarter Adjusted EBITDA declined 5% FX-neutral.
Filing Explained
After the quarter closed, Auna terminated a Colombian oncology risk-sharing contract covering about 500,000 lives and representing about
Key Figures
Key Terms
FX-neutral financial
Adjusted EBITDA financial
Free Cash Flow financial
Leverage Ratio financial
Public-Private Partnership technical
non-IFRS financial measures financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were AUNA's third-quarter 2026 revenue and Adjusted EBITDA?
What is AUNA's full-year 2026 guidance?
When is AUNA's Trecca facility expected to open, and what capacity will it add?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2026
Commission File Number: 001-41982
Auna S.A.
(Exact name of registrant as specified in its charter)
6, rue Jean Monnet
L-2180 Luxembourg
Grand Duchy of Luxembourg
+51 1-205-3500
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
| Form 20-F |
X |
Form 40-F |
TABLE OF CONTENTS
| EXHIBIT | |
| 99.1 | Press release dated November 17, 2026 — Auna announces 3Q26 Financial Results |
| 99.2 | Condensed Consolidated Interim Financial Statements as of and for the nine months ended September 30, 2026 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Auna S.A. | |||
| By: | /s/ Gisele Remy | ||
| Name: | Gisele Remy | ||
| Title: | Chief Financial Officer | ||
Date: November 17, 2026
Exhibit 99.1
Auna Announces 3Q26 Financial Results
Auna reports 10% FX-Neutral Revenue Growth and Continued Strong Cash Generation in 3Q2026;
Mexico Returns to Year-over-Year Adjusted EBITDA Growth;
Profitability Pressured by Specific Headwinds in Colombia and Peru
Leverage Improves to 3.5x
Luxembourg, November 17, 2026 – Auna (NYSE: AUNA) (“Auna” or the “Company”), a leading healthcare platform in Latin America with operations in Mexico, Peru, and Colombia, announced today unaudited financial results for the third quarter ended September 30, 2026 (“Third quarter 2026” or “3Q26”). Financial results are expressed in Peruvian Soles (“S/” or “PEN” or “Soles”) and are presented in accordance with International Financial Reporting Standards (“IFRS”), unless otherwise noted.
3Q’26 Consolidated Highlights
| ● | Revenue increased 10% YoY FXN and 19% YoY as reported to S/1,325 million, with sequential growth of 3% FXN and 7% as reported |
| ● | Adjusted EBITDA was S/231 million, decreasing 4.6% FXN while remaining flat as reported. Sequentially, Adjusted EBITDA was stable FXN and increased 2% as reported |
| ● | Mexico Segment Adjusted EBITDA increased 5% YoY in local currency, marking its first year-over-year growth in 2026 |
| ● | Adjusted EBITDA Margin of 17.5%, compared to 18.4% in 2Q26 |
| ● | Year to date Net Cash from Operating Activities increased 62% YoY to S/713 million, while Free Cash Flow increased 95% to S/626 million |
| ● | Leverage Ratio improved to 3.5x |
| ● | Oncology MLR remained stable at 50.7% |
| ● | Number of surgeries increased 12% YoY to 23,932 |
| ● | Number of days hospitalized increased 6% YoY to 144,041 |
| ● | Number of chemotherapy and radiotherapy sessions increased 7% YoY |
1
Recent Developments
Centro Ambulatorio Trecca Public-Private Partnership Enters Construction Phase
On November 3, 2026, Centro Ambulatorio Trecca formally entered its construction phase following the fulfillment of all conditions precedent under Auna’s Public-Private Partnership (PPP) with EsSalud. This milestone keeps the project on schedule and represents an important step in expanding access to quality healthcare in Peru. The commencement was marked by an event attended by national authorities, including the President of the Republic of Peru, Keiko Fujimori, as well as EsSalud representatives and Auna’s leadership.
Structured as a 20-year, capital-light concession ring-fenced at the project level, construction expenditures will be reimbursed through progress certificates. The 23-story facility will provide Auna with access to a largely untapped segment of Peru’s healthcare market serving approximately six million EsSalud-insured residents in Lima. Once operational, currently expected by late 2028, the facility is projected to increase EsSalud’s healthcare capacity in metropolitan Lima by approximately 20% and support more than three million patient visits annually. Operations will be supported by monthly EsSalud payments based on contractually established minimum service volumes, providing long-term revenue visibility.
Full-Year 2026 Guidance Update
As announced on October 22, 2026, Auna reaffirms its full-year revenue guidance within the previously announced range of 10% to 14% FX-neutral growth and capital expenditures guidance of approximately 4% of consolidated revenues.
Auna revised its full-year 2026 Adjusted EBITDA outlook, reflecting higher-than-anticipated operating costs in Colombia, including adverse medical-costs under a specific oncology risk-sharing contract and regulatory price caps on certain high-cost oncology medications. The Company now expects full-year Adjusted EBITDA to remain broadly stable or slightly down year-over-year, compared to its previous guidance of 10% to 14% FX-neutral growth.
Message from Auna’s Executive Chairman and President
The third quarter of 2026 reflected continued strong commercial momentum across our markets, with revenue increasing 10% on an FX-neutral basis. Adjusted EBITDA declined 5% FX-neutral, primarily reflecting profitability pressures in Colombia and Peru, partially offset by improving performance in Mexico. The quarter marked an important milestone
2
in Mexico’s operational recovery, with Segment Adjusted EBITDA returning to year-over-year growth, while continued strong cash generation supported further deleveraging.
In Peru, our resilient integrated model produced revenue growth of 6% year-over-year. The Peru Healthcare network benefited from strong surgical volumes, up 21%, alongside a greater focus on high-complexity procedures. At Oncosalud, we prioritized and grew higher-retention B2B accounts, including two new agreements to onboard 4,000 members. Adjusted EBITDA was impacted by penalties arising from the reconciliation of prior years’ receivables, as well as higher pharmacy and clinical payroll costs associated with increased patient volumes.
In Mexico, we are seeing tangible results from the commercial and operational initiatives implemented earlier this year. Segment Adjusted EBITDA increased 5% year-over-year in local currency, marking its first quarter of year-over-year growth in 2026. This improvement was driven by strong performance in the Monterrey Healthcare network, supported by higher surgical and oncology volumes and improved capacity utilization, which more than offset softer results at Auna Seguros following changes in VAT deductibility. With double-digit oncology revenue growth and improving operating efficiency, we remain focused on further improving this recovery and translating higher utilization into stronger profitability.
In Colombia, revenue increased 12% in local currency, supported by increased hospital capacity in Montería and continued growth in our PGP arrangements. However, Segment Adjusted EBITDA declined 30% in local currency, primarily reflecting two items: first, extraordinary adverse medical-costs under a specific oncology risk-sharing contract, where utilization and treatment costs significantly exceeded contractual assumptions; and second, regulatory price caps on certain high-cost oncology medications. These were further compounded by higher personnel costs across the segment. We have terminated the risk sharing contract to limit further exposure as it represented approximately 4% of Colombia´s revenues and have engaged legal counsel to review all recovery options under the contract. We remain focused on strengthening contract economics, improving operating efficiency, and restoring profitability.
Consolidated cash flow generation remained a significant strength of our platform. Year-to-date Net Cash from Operating activities increased 62% year-over-year to S/713 million, while Free Cash Flow increased 95% to S/626 million, supported by disciplined working capital management, and lower tax payments. This performance contributed to a reduction in net debt and an improvement in our leverage ratio towards 3.5x, bringing it closer to our medium-term target of below 3.0x.
We reached an important milestone with the commencement of construction of Centro Ambulatorio Trecca in Lima. This capital-light public-private partnership will significantly expand our addressable market and provide long-term contractual revenue visibility, reinforcing our strategy of developing capital-efficient growth opportunities.
3
Looking ahead, as discussed at our recent 2026 Investor Day, we remain confident in the underlying growth trajectory of our business. We reaffirm our full-year 2026 revenue guidance, expecting FX-neutral growth within our 10% to 14% range. However, reflecting the profitability pressures discussed above, particularly in Colombia, we now expect full-year Adjusted EBITDA to remain broadly stable or slightly down year-over-year. Capital expenditures guidance remains unchanged at approximately 4% of revenues.
We remain focused on accelerating growth in Mexico, restoring profitability in Colombia, improving earnings quality and operating efficiency in Peru, and translating our commercial momentum into even stronger cash generation and growing, sustainable returns for our shareholders. We are committed to disciplined execution, strengthening our financial performance, and creating long-term shareholder value.
Overview of 3Q26 Consolidated Results
Revenues increased 10% YoY FXN and 19% as reported to S/1,325 million, with growth measured in local currency (“LC”) across all three markets: 16% in Mexico, 6% in Peru, and 12% in Colombia. In Mexico, growth was driven by higher surgery and oncology volumes at the Monterrey Healthcare network, partially offset by softer performance in Auna Seguros. In Peru, revenue growth was supported by increased healthcare activity, particularly high-complexity procedures and continued growth in Oncosalud’s B2B business. In Colombia, revenue growth benefited from expanded hospital capacity.
Adjusted EBITDA decreased 5% YoY FXN and remained flat as reported at S/231 million, with an Adjusted EBITDA margin of 17.5%. In LC, Segment Adjusted EBITDA increased 5% in Mexico, while declining 6% in Peru and 30% in Colombia. Mexico recorded its first quarter of year-over-year Segment Adjusted EBITDA growth in 2026, driven by improving profitability in the Monterrey Healthcare network, partially offset by softer results at Auna Seguros. In Peru, profitability was impacted by penalties related to the reconciliation of prior years’ receivables, as well as higher MLR from a larger mix of healthcare plans and the ramp up of new B2B oncology plans. In Colombia, profitability was primarily affected by adverse medical-costs under a specific oncology risk-sharing contract, which Auna has since terminated and regulatory price caps on certain high-cost oncology medications.
Reported results were impacted by foreign exchange fluctuations, including a 3% appreciation of the Mexican Peso (MXN) and a 20% appreciation of the Colombian Peso (COP) both against the Peruvian Sol (PEN).
4
Net finance costs were S/112 million in 3Q26, compared to S/72 million in 3Q25. The increase primarily reflected a S/40 million non-cash FX gain recognized in 3Q25 that did not recur in 3Q26, due to Auna resetting its USD/PEN call spread to 3.40-3.80 in Q425. The remainder of the change was due to an increase in Finance costs consisting of (i) a S/6 million non-cash finance expense related to the future purchase obligation for IMAT Oncomedica in 3Q26 versus S/1 million in 3Q25; and (ii) Interest expense and other costs of S/114 in 3Q26 versus S/115 in 3Q25, and partially offset by Finance income of S/7 million in 3Q26 versus S/4 million in 3Q25. Excluding non-cash effects, Net finance costs were S/107 million in 3Q26, compared to S/110 million in 3Q25.
Net Income was S/24 million in 3Q26, compared to S/53 million in 3Q25 primarily reflecting the absence of the significant S/40 million non-cash FX gain recorded in the prior-year period, partially offset by S/20 million in lower income tax expenses. On a per-share basis, Net Income was S/0.27, based on a weighted average of 74,235,734 basic and diluted shares.
Adjusted Net Income was S/35 million in 3Q26, compared to S/58 million in 3Q25, primarily reflecting the non-cash FX effects described above, partially offset by lower income tax expenses. On a per-share basis, Adjusted Net Income was S/0.41, based on a weighted average of 74,235,734 basic and diluted shares.
Business performance
HEALTHCARE SERVICES MEXICO
(Explanations of variances are in local currency unless expressed otherwise)
Auna’s Healthcare Services and Auna Seguros’ operations in Mexico accounted for 24% of consolidated revenues and 36% of consolidated Adjusted EBITDA in the quarter.
Healthcare Services Mexico
(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)
| Δ 3Q'26 vs 3Q'25 | Δ 3Q'26 vs 2Q'26 | Δ YTD 26 vs YTD 25 | ||||||||||||||||||||||||||||||||||||
| Healthcare Services Mexico Key Operating Metrics | 3Q'26 (USD) | 3Q'26 | YTD 26 | As Reported | L.C. | As Reported | L.C. | As Reported | L.C. | |||||||||||||||||||||||||||||
| Beds | # | 708 | 708 | 0 | % | 0 | % | 0 | % | |||||||||||||||||||||||||||||
| Surgeries | 6 | 16 | 12 | % | 12 | % | 7 | % | ||||||||||||||||||||||||||||||
| Emergency treatments | #(000) | 8 | 24 | 9 | % | 1 | % | 1 | % | |||||||||||||||||||||||||||||
| Radiotherapy & Chemotherapy | #(000) | 5 | 14 | 34 | % | -1 | % | 62 | % | |||||||||||||||||||||||||||||
| Total number of days hospitalized | #(000) | 27 | 77 | 5 | % | 6 | % | 2 | % | |||||||||||||||||||||||||||||
| Operating capacity utilization | % | 50.5 | % | 49.0 | % | 2.9 p.p. | 0.6 p.p. | 1.3 p.p. | ||||||||||||||||||||||||||||||
| Total capacity utilization | % | 41.1 | % | 39.9 | % | 2.0 p.p. | 2.0 p.p. | 0.7 p.p. | ||||||||||||||||||||||||||||||
| Key Financial Metrics | ||||||||||||||||||||||||||||||||||||||
| Segment Revenue | 92 | 316 | 895 | 20 | % | 16 | % | 5 | % | 6 | % | 15 | % | 9% | ||||||||||||||||||||||||
| Segment Adjusted EBITDA | 24 | 83 | 234 | 8 | % | 5 | % | 7 | % | 8 | % | -4 | % | -9% | ||||||||||||||||||||||||
| Segment Adjusted EBITDA margin | % | 26.3 | % | 26.2 | % | -2.7 p.p. | 0.4 p.p. | -5.2 p.p. | ||||||||||||||||||||||||||||||
5
Segment revenue in Mexico increased 16% YoY in LC, driven by an 18% increase in the Monterrey Healthcare Services network. Sequentially, Segment revenue grew 6% compared to 2Q26, with Healthcare Services remaining the primary growth driver. Growth was supported by higher volumes across surgeries, intensive care, and chemotherapy sessions, reflecting the continued benefits of operational initiatives implemented in previous quarters.
Auna continued to benefit from improved tier classifications with two key payors at Doctors Hospital (“DH”), its largest healthcare facility, where patient volumes associated with these payors increased 25% and related revenues surged 63% YoY. Total surgery revenues at DH also increased 22% YoY. Additionally, the renewal of the ISSSTELEON B2B agreement at OCA, which included improved pricing that reflects the complexity of services provided, contributed to a 16% YoY increase in related revenues. Private out-of-pocket revenues across the network increased 11% YoY, while patient volumes from surgical and hemodynamic packages tripled over the same period.
In oncology, radiotherapy and chemotherapy revenues increased 73% YoY and 5% QoQ, representing 10% of Monterrey’s network revenues in 3Q26, up from 7% in 3Q25.
Operationally, approximately 52% of the network’s productive physicians increased their service volumes during the quarter, while nursing staffing coverage and retention improved compared to 2025. The network also strengthened physician onboarding criteria, with a greater focus on productivity. During the quarter, Auna onboarded 28 physicians who actively treated patients for at least two months and met minimum billing thresholds, primarily in specialties including traumatology, cardiology, and general medicine.
Higher volumes across surgeries, emergency treatments, hospitalizations, and intensive care contributed to total capacity utilization of 41.1%, an increase of 2.0 percentage points both YoY and QoQ.
Segment Adjusted EBITDA increased 5% YoY in local currency, with an Adjusted EBITDA margin of 26.3%. This marked the segment’s first quarter of year-over-year Adjusted EBITDA growth in 2026, reflecting continued progress in its operational recovery. Within the segment, the Monterrey Healthcare network’s Adjusted EBITDA increased 10% YoY, reaching a margin of 28%, despite higher pharmacy costs related to changes in service mix, investments in talent retention, and the implementation of a new mandatory medical insurance benefit for employees.
Sequentially, Segment Adjusted EBITDA increased 8% in local currency, supported by 9% growth in the Monterrey Healthcare network’s Adjusted EBITDA and a 0.7 percentage point improvement in its margin compared to 2Q26. These results provide further evidence of the ongoing recovery in the network’s operating profitability.
Conversely, Auna Seguros revenues remained flat YoY, while Adjusted EBITDA was negatively impacted by a new 2026 sector-wide regulation restricting VAT deductibility for insurance products.
6
PERU OPERATIONS: HEALTHCARE SERVICES PERU AND ONCOSALUD PERU
Auna’s Healthcare Services and Oncosalud Peru accounted for 39% of consolidated revenues and 45% of consolidated Adjusted EBITDA in the quarter.
Peru Consolidated (Healthcare Services Peru and Oncosalud Peru)
(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)
| Healthcare Services Peru and Oncosalud Peru Key Financial Metrics | 3Q'26 (USD) | 3Q'26 | YTD 26 | Δ 3Q'26 vs 3Q'25 | Δ 3Q'26 vs 2Q'26 | Δ YTD 26 vs YTD 25 | ||||||||||||||||||||
| Consolidated Revenue | 150 | 516 | 1,528 | 6 | % | 1 | % | 7% | ||||||||||||||||||
| Healthcare Services Peru | 89 | 307 | 885 | 10 | % | 4 | % | 9% | ||||||||||||||||||
| Oncosalud Peru | 94 | 323 | 954 | 10 | % | 2 | % | 11% | ||||||||||||||||||
| Holding and Eliminations (*) | (114 | ) | (310 | ) | 35 | % | 13 | % | 24% | |||||||||||||||||
| Consolidated Peru Adjusted EBITDA | 30 | 104 | 304 | -6 | % | 3 | % | -3% | ||||||||||||||||||
| Healthcare Services Peru | 11 | 37 | 102 | -16 | % | 6 | % | -15% | ||||||||||||||||||
| Oncosalud Peru | 20 | 68 | 202 | 0 | % | 1 | % | 4% | ||||||||||||||||||
| Consolidated Peru Adj. EBITDA margin | % | 20.2 | % | 19.9 | % | -2.6 p.p. | 0.4 p.p. | -2.1 p.p. | ||||||||||||||||||
| Healthcare Services Peru | 11.9 | % | 11.5 | % | -3.8 p.p. | 0.2 p.p. | -3.2 p.p. | |||||||||||||||||||
| Oncosalud Peru | 20.9 | % | 21.2 | % | -2.0 p.p. | -0.1 p.p. | -1.4 p.p. | |||||||||||||||||||
(*) Relates to intersegment revenue elimination.
Healthcare Services Peru
| Healthcare Services Peru Key Operating Metrics | 3Q'26 (USD) | 3Q'26 | YTD 26 | Δ 3Q'26 vs 3Q'25 | Δ 3Q'26 vs 2Q'26 | Δ YTD 26 vs YTD 25 | ||||||||||||||||||||
| Beds | # | 389 | 389 | 1 | % | 0 | % | 1% | ||||||||||||||||||
| Surgeries | #(000) | 6 | 18 | 21 | % | 10 | % | 11% | ||||||||||||||||||
| Emergency treatments | #(000) | 54 | 151 | 10 | % | 4 | % | 12% | ||||||||||||||||||
| Chemotherapies & Radiotherapies | #(000) | 14 | 40 | 18 | % | 6 | % | 6% | ||||||||||||||||||
| Total number of days hospitalized | #(000) | 32 | 94 | 6 | % | 2 | % | 8% | ||||||||||||||||||
| Operating capacity utilization | % | 92.6 | % | 91.4 | % | 4.9 p.p. | 0.6 p.p. | 7.1 p.p. | ||||||||||||||||||
| Total capacity utilization | % | 89.2 | % | 88.1 | % | 3.9 p.p. | 0.6 p.p. | 6.0 p.p. | ||||||||||||||||||
| Key Financial Metrics | ||||||||||||||||||||||||||
| Revenue | 89 | 307 | 885 | 10 | % | 4 | % | 9% | ||||||||||||||||||
| External revenues | 60 | 207 | 616 | 3 | % | 0 | % | 5% | ||||||||||||||||||
| Intercompany revenue | 29 | 100 | 269 | 29 | % | 13 | % | 21% | ||||||||||||||||||
| Segment Adjusted EBITDA | 11 | 37 | 102 | -16 | % | 6 | % | -15% | ||||||||||||||||||
| Segment Adjusted EBITDA margin | % | 11.9 | % | 11.5 | % | -3.8 p.p. | 0.2 p.p. | -3.2 p.p. | ||||||||||||||||||
7
Oncosalud Peru
| Oncosalud Peru Key Operating Metrics | 3Q'26 (USD) | 3Q'26 | YTD 26 | Δ 3Q'26 vs 3Q'25 | Δ 3Q'26 vs 2Q'26 | Δ YTD 26 vs YTD 25 | ||||||||||||||||||||
| Plan memberships | #(000) | 1,442 | 1,442 | 3 | % | -2 | % | 3% | ||||||||||||||||||
| Oncological Plans | #(000) | 973 | 973 | -2 | % | -3 | % | -2% | ||||||||||||||||||
| Average monthly revenue per plan membership | 18.98 | 65.15 | 64.02 | 5 | % | 3 | % | 5% | ||||||||||||||||||
| Preventive check-ups | #(000) | 25 | 82 | -14 | % | -4 | % | -13% | ||||||||||||||||||
| Patients treated | #(000) | 56 | 154 | 34 | % | 10 | % | 28% | ||||||||||||||||||
| MLR | % | 58.7 | % | 4.2 p.p. | ||||||||||||||||||||||
| Oncological Plans | % | 50.7 | % | 1.4 p.p. | ||||||||||||||||||||||
| Key Financial Metrics | ||||||||||||||||||||||||||
| Revenue | 94 | 323 | 954 | 10 | % | 2 | % | 11% | ||||||||||||||||||
| External revenues | 90 | 308 | 912 | 8 | % | 1 | % | 9% | ||||||||||||||||||
| Intercompany revenue | 4 | 14 | 41 | 96 | % | 9 | % | 53% | ||||||||||||||||||
| Segment Adjusted EBITDA | 20 | 68 | 202 | 0 | % | 1 | % | 4% | ||||||||||||||||||
| Segment Adjusted EBITDA margin | % | 20.9 | % | 21.2 | % | -2.0 p.p. | -0.1 p.p. | -1.4 p.p. | ||||||||||||||||||
Total revenue in Peru increased 6% YoY to S/516 million in 3Q26. Healthcare Services Peru revenue increased 10% YoY, supported by higher surgery, emergency, and oncology volumes. Emergency treatments increased 10% YoY, benefiting from commercial initiatives with corporate accounts, while surgeries grew 21%, alongside a greater focus on high-complexity procedures and higher average revenue per surgery. Total bed capacity increased 1% YoY to 389 beds, including the addition of four ICU beds. Hospitalization days increased 6% YoY, while total capacity utilization reached 89.2%, an improvement of 3.9 percentage points.
Oncosalud Peru revenue increased 10% YoY, supported by annual pricing adjustments and 3% growth in total plan memberships. Auna continued to prioritize B2B accounts with stronger retention characteristics, adding two new agreements to onboard 4,000 members beginning in 4Q26.
Preventive check-ups, as planned, declined 14% YoY, reflecting a more targeted approach to screening members at higher risk of developing breast, colorectal, cervical, or prostate cancers. Meanwhile, patients treated increased 34% YoY, driven by increased healthcare plan memberships and the initial utilization among newly onboarded B2B members.
Oncosalud's overall MLR increased 4.2 percentage points year-to-date to 58.7%, while the Oncology MLR increased 1.4 percentage points to 50.7%. The overall MLR increase reflects a greater mix of healthcare plans while the Oncology MLR increase reflects the initial higher average MLR from newly onboarded B2B accounts.
Consolidated Peru Adjusted EBITDA decreased 6% YoY to S/104 million in 3Q26, with an Adjusted EBITDA margin of 20.2%, compared to 22.8% in 3Q25. Profitability was impacted by higher pharmacy costs associated with the onboarding of new B2B accounts and
8
increased clinical and nursing payroll expenses to support growing hospitalization and emergency volumes while maintaining capacity and quality standards. Results were also affected by penalties related to billing matters arising from the reconciliation of prior years' receivables. Excluding impacts related to billing matters, EBITDA growth in the quarter would have been broadly stable YoY.
HEALTHCARE SERVICES COLOMBIA
(Explanations of variances are in local currency unless expressed otherwise)
Auna’s Healthcare services operations in Colombia accounted for 37% of consolidated revenues and 19% of consolidated Adjusted EBITDA in the quarter.
(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)
| Δ 3Q'26 vs 3Q'25 | Δ 3Q'26 vs 2Q'26 | Δ YTD 26 vs YTD 25 | ||||||||||||||||||||||||||||||||||||
| Healthcare Services Colombia Key Operating Metrics | 3Q'26 (USD) | 3Q'26 | YTD 26 | As Reported | L.C. | As Reported | L.C. | As Reported | L.C. | |||||||||||||||||||||||||||||
| Beds | 1,155 | 1,155 | 2 | % | 2 | % | 2 | % | ||||||||||||||||||||||||||||||
| Protected Lives | 3,209 | 3,209 | 6 | % | 2 | % | 6 | % | ||||||||||||||||||||||||||||||
| Surgeries | 12 | 34 | 7 | % | 8 | % | 5 | % | ||||||||||||||||||||||||||||||
| Emergency treatments | 39 | 116 | 6 | % | 3 | % | 5 | % | ||||||||||||||||||||||||||||||
| Chemotherapies & Radiotherapies | #(000) | 37 | 109 | 0 | % | 4 | % | 1 | % | |||||||||||||||||||||||||||||
| Total number of days hospitalized | #(000) | 85 | 248 | 6 | % | 5 | % | 4 | % | |||||||||||||||||||||||||||||
| Operating capacity utilization | % | 88.8 | % | 86.8 | % | 2.7 p.p | 0.0 p.p | 0.7 p.p | ||||||||||||||||||||||||||||||
| Total capacity utilization | % | 80.3 | % | 78.5 | % | 3.3 p.p | 1.1 p.p | 1.8 p.p | ||||||||||||||||||||||||||||||
| Key Financial Metrics | ||||||||||||||||||||||||||||||||||||||
| Revenue | 144 | 494 | 1,321 | 34 | % | 12 | % | 16 | % | 4 | % | 25 | % | 13% | ||||||||||||||||||||||||
| Segment Adjusted EBITDA | 13 | 43 | 145 | -16 | % | -30 | % | -22 | % | -30 | % | -4 | % | -13% | ||||||||||||||||||||||||
| Segment Adjusted EBITDA margin | % | 8.8 | % | 10.9 | % | -5.1 p.p | -4.3 p.p | -3.3 p.p. | ||||||||||||||||||||||||||||||
Segment revenue in Colombia increased 12% YoY in local currency, supported by a 6% increase in protected lives, 7% growth in surgeries, and 6% increases in both emergency treatments and hospitalization days. Chemotherapy and radiotherapy volumes remained stable YoY and increased 4% QoQ.
Operating performance benefited from expanded capacity at IMAT Oncomedica in Montería, capturing growing demand for high-complexity care. During 3Q26, the hospital reactivated 18 adult ICU beds and added 24 hospitalization beds.
Auna continued diversifying its payor base to reduce exposure to government-intervened payors. Revenues from intervened payors represented 15% of Colombia's segment revenues in 3Q26, compared to 16% in 3Q25. Private payor revenues increased 22% YoY, accounting for 18% of segment revenues.
9
PGP contracts in Antioquia, covering cardiovascular, ambulatory, and oncology services, accounted for 23% of Colombia's segment revenues, compared to 18% in 3Q25. These risk-sharing arrangements covered approximately 3.2 million lives at quarter-end, an increase of 6% YoY, and deliver more engagement with payors and their populations and greater cash flow predictability for Auna.
After the close of the quarter, the Company terminated an oncology risk-sharing contract that started in 2025 covering approximately 500,000 lives and represented approximately 4% of Colombia’s revenues, following a significantly higher incidence of advanced-stage cancers than anticipated under the contractual assumptions agreed with the payor.
Revenues in Montería and Barranquilla increased 15% and 10% YoY, respectively, and together represented 47% of segment revenues. Total capacity utilization reached 80.3%, an increase of 3.3p.p. YoY, returning to levels observed in 2024, before the intervention of Nueva EPS.
Segment Adjusted EBITDA decreased 30% YoY in local currency, with an Adjusted EBITDA margin of 8.8%, compared to 13.9% in 3Q25. Margins were affected by government-imposed price caps on certain high-cost oncology medications impacting the quarter only partially since mid-August, as well as initial operating costs associated with the capacity expansion in Montería. Additional payroll pressures reflected mandatory wage increases and the statutory reduction in the standard workweek, which resulted in higher overtime expenses.
The decline was also driven by adverse medical costs related to the abovementioned oncology risk-sharing contract, where an unexpectedly high incidence of advanced-stage cancer cases among the covered population resulted in treatment costs exceeding the contractual assumptions. The contract was terminated after the close of the quarter to limit further exposure and protect future profitability.
10
Balance Sheet & Cash Flow
Consolidated Debt
(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)
| Sep-26 | Δ Sep-26 vs | |||||||||||||||||||||||
| (USD) | Sep-26 | Dec-25 | Sep-25 | Sep-25 | Dec-25 | |||||||||||||||||||
| (+) Loans and borrowings | 1,049 | 3,600 | 3,533 | 3,526 | 2 | % | 2 | % | ||||||||||||||||
| Short term debt | 135 | 465 | 316 | 658 | -29 | % | 47 | % | ||||||||||||||||
| Long term debt | 913 | 3,136 | 3,216 | 2,868 | 9 | % | -2 | % | ||||||||||||||||
| (+) Lease Liabilities | 43 | 146 | 124 | 129 | 13 | % | 18 | % | ||||||||||||||||
| Gross Debt | 1,091 | 3,746 | 3,656 | 3,655 | 3 | % | 2 | % | ||||||||||||||||
| (-) Cash and cash equivalents / marketable securities | 179 | 614 | 335 | 226 | 172 | % | 83 | % | ||||||||||||||||
| Net Debt | 913 | 3,133 | 3,321 | 3,429 | -8.6 | % | -5.7 | % | ||||||||||||||||
| Leverage Ratio | 3.5 | x | 3.6 | x | 3.6 | x | -0.1 | x | -0.1 | x | ||||||||||||||
Gross Debt at the close of 3Q26 increased 2%, or S/90 million, versus 4Q25, to S/3,746 million. This increase was driven mainly by non-cash FX effects rather than an increase in underlying debt. The net changes reflect: (i) a negative non-cash effect of S/97 million associated with the depreciation of the PEN against the COP, the USD and the MXN of 16%, 2% and 2%, respectively; and (ii) higher accrued interest of S/46 million related to the Term Loan maturing 2030 and 2032 Senior Secured Notes. These effects were partially offset by (iii) a S/52 million reduction in short-term debt.
Leverage Ratio improved to 3.5x at the end of 3Q26. Compared to 3Q25 this improvement reflects an increase in cash position at the end of the period, partially offset by lower Adjusted LTM EBITDA and slightly higher gross debt driven by the aforementioned non-cash FX effects. On a sequential basis, the ratio also improved due to the increase in cash. Auna remains committed to a medium-term leverage target of below 3.0x.
11
Consolidated Debt Amortization Profile
(Figures in millions of Soles, unless expressed otherwise)
| Total | Leases | Y1 | Y2 | Y3 | Y4 | Y5 | Y6+ | |||||||||||||||||||||||||
| Loans and Borrowings | 3,600 | 465 | 270 | 350 | 760 | 463 | 1,292 | |||||||||||||||||||||||||
| Financial Leases | 53 | 16 | 10 | 8 | 12 | 3 | 4 | |||||||||||||||||||||||||
| Operating Leases | 93 | 93 | ||||||||||||||||||||||||||||||
| Gross Debt | 3,746 | 93 | 481 | 280 | 358 | 772 | 466 | 1,296 | ||||||||||||||||||||||||
As of 3Q26. Excludes interest. Reflects figures post-refinancing. Y1 = October 2026 to September 2027, Y2 = October 2027 to September 2028, Y3 = October 2028 to September 2029, Y4 = October 2029 to September 2030, Y5 = October 2030 to September 2031, and Y6+ = October 2031 to September 2035.
Cashflow and Cash Conversion Cycle
(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)
Cashflow
| YTD 26 (USD) | YTD 26 | YTD 25 | Δ YTD 26 vs YTD 25 | |||||||||||||
| Net cash from operating activities | 208 | 713 | 440 | 62 | % | |||||||||||
| Net cash used in investing activities | (25 | ) | (86 | ) | (119 | ) | -27 | % | ||||||||
| Net cash used in financing activities | (106 | ) | (363 | ) | (336 | ) | 8 | % | ||||||||
| Cash and cash equivalents at the end of the period | 179 | 614 | 226 | 172 | % | |||||||||||
Cash Conversion Cycle
| LTM Sep-25 | LTM Jun-26 | LTM Sep-26 | ||||||||||
| Days Sales Outstanding | 91 | 89 | 88 | |||||||||
| Days Inventory Outstanding | 42 | 41 | 39 | |||||||||
| Days Payable Outstanding | 142 | 141 | 142 | |||||||||
| Cash Conversion Cycle | -9 | -10 | -15 | |||||||||
*Measured on an average basis according to last twelve months results.
Net cash from operating activities was S/713 million for the nine months ended September 30, 2026 versus S/440 million in the nine months ended September 30, 2025, and included a S/172 million increase in cash generated from operating activities, mainly related to a reduction in accounts receivable days and an improvement in collections in Peru and Mexico, as well as stable collections in Colombia, and to S/101 million in lower tax payments, primarily reflecting more efficient management of tax returns in Colombia, including the timely recovery of tax balances owed to Auna.
12
Net cash used in investing activities for the nine months ended September 30, 2026 was S/86 million, a decrease of 27% YoY, or S/33 million versus the comparable period last year. In YTD 2026 organic maintenance CapEx was S/111 million and included (i) S/71 million in investments for infrastructure refurbishments and acquisition of medical equipment; (ii) S/39 million in Hospital Information systems and ERP implementations, and (iii) a S/2 million payment to the Opción Oncología doctors for the brand acquisition. Additional investing cash flows included (iv) S/ 29 million cash inflow from Auna Seguros portfolio rebalancing, partially offset by (v) S/ 6 million earnout payment to IMAT Oncomedica shareholders.
In the nine months ended September 30, 2025, investing activities included: S/113 million in organic maintenance CapEx, including (i) S/66 million in investments for infrastructure refurbishments and acquisition of medical equipment; (ii) S/39 million in Hospital Information systems and ERP implementations; and (iii) an S/8 million payment to the Opción Oncología doctors for the brand acquisition. Other cash from investing activities included (iv) S/5 million in cash and cash equivalent inflows from Auna Seguros portfolio rebalancing of investments toward liquid securities, (v) a S/15 million payment to former OCA shareholders for holdback obligations, and (vi) a S/6 million earnout payment to IMAT Oncomedica shareholders.
Net cash used in financing activities was S/363 million, an increase of 8% or S/27 million, for the nine months ended September 30, 2026 versus the comparable period last year. Cash used in financing activities during the period included: (i) S/228 million in interest payments and hedge premium payments, (ii) S/34 million in interest payments for working capital facilities, and (iii) a S/101 million decrease in working capital borrowings. For the comparable nine months ended September 30, 2025, cash used in financing included: (i) S/247 million in interest and hedge premium payments, (ii) S/50 million in interest payments for working capital facilities, and (iii) a S/39 million decrease in working capital borrowings.
About AUNA
Auna is a leading healthcare platform in Latin America with operations in Mexico, Peru, and Colombia, prioritizing prevention and concentrating on high-complexity diseases that contribute the most to healthcare expenditures. Our mission is to transform healthcare by providing access to a highly integrated healthcare offering in the underpenetrated markets of Spanish-Speaking Americas. Founded in 1989, Auna has built one of Latin America′s largest modern healthcare platforms that consists of a horizontally integrated network of healthcare facilities and a vertically integrated portfolio of oncological plans and selected general healthcare plans. As of September 30, 2026, Auna’s network included 31 healthcare network facilities, consisting of hospitals, outpatient, prevention and wellness facilities with a total of 2,361 beds, and 1.4 million healthcare plans.
For more information visit www.aunainvestors.com
13
Conference Call Details
When: 8:00 a.m. Eastern time, November 18, 2026
Who: Mr. Suso Zamora, Executive Chairman of the Board and President; Mrs. Gisele Remy, Chief Financial Officer and Executive Vice President; Mr. Lorenzo Massart, Executive Vice President of Strategy and Equity Capital Markets.
Dial-in:
+1 833-461-5787 (U.S. domestic), +1 585-542-9983 (International)
International Dial-Ins: https://help.events.q4inc.com/eahc/international-dial-in-numbers
Meeting ID: 489 711 788 (Passcode)
Webcast: click here
Definitions and Concepts
Figures in US dollars (US$ or USD) for 3Q26 are presented for indicative purposes and were calculated using an FX rate of US$1= S/3.4330. All comparisons in this announcement are year-over-year (“YoY”), unless otherwise noted; additionally, results are presented in an FX neutral basis (“FXN”) for consolidated revenues, consolidated cost of sales and services, consolidated selling and administrative expenses and consolidated adjusted EBITDA, as well as, in local currency for the Mexico and Colombia segments, to eliminate the effect of foreign exchange, or “FX,” volatility between the comparison periods.
Financial results are preliminary and subject to year-end audit.
Use of Non-IFRS Financial Measures
This release includes “non-IFRS financial measures”, including: EBITDA, EBITDA Margin, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted LTM EBITDA, Segment EBITDA, Segment EBITDA Margin, Segment Adjusted EBITDA, Segment Adjusted EBITDA Margin, Consolidated Peru Adjusted EBITDA, Consolidated Peru Adjusted EBITDA Margin, Adjusted Net Income, Adjusted Basic and Diluted EPS, Leverage Ratio, Free Cash Flow, and FX Neutral because we believe they assist investors and analysts in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance.
In addition, management and our board of directors use these non-IFRS financial measures to assess our financial performance and believe they are helpful in highlighting trends in our core operating performance, while other measures can differ significantly depending on long-term strategic decisions regarding the growth of our business. These are not measurements of operating performance under IFRS and have limitations as analytical tools. You should not consider such measures either in isolation or as substitutes for analyzing our results as reported under IFRS. Additionally, our calculations of EBITDA, Segment EBITDA, Adjusted EBITDA, Adjusted Net Income, EBITDA Margin, Adjusted EBITDA Margin, FX Neutral and Leverage Ratio may be different from the calculations used by
14
other companies for similarly titled measures, including our competitors, and therefore may not be comparable to those of other companies.
EBITDA: is calculated as profit (loss) before tax for the period plus net finance cost and depreciation and amortization. EBITDA is a key metric used by management and our board of directors to assess our financial performance.
EBITDA Margin: is calculated as EBITDA divided by total revenue from contracts with customers.
Adjusted EBITDA: is calculated as profit (loss) before tax for the period plus net finance cost, depreciation and amortization, pre-operating expenses for projects under construction, business development (income) expenses for expansion into new markets, change in fair value of earn-out liabilities, stock-based consideration and personnel non-recurring compensation.
Adjusted EBITDA Margin: is calculated as Adjusted EBITDA divided by total revenue from contracts with customers.
Adjusted Last Twelve Month (“LTM”) EBITDA: is calculated by adding the last four quarters beginning with the corresponding period.
Segment EBITDA: is calculated as segment profit before tax plus net finance cost and depreciation and amortization.
Segment EBITDA Margin: is calculated as segment EBITDA divided by total segment revenue from contracts with customers.
Segment Adjusted EBITDA: is calculated as segment profit (loss) before tax for the period plus net finance cost, depreciation and amortization, pre-operating expenses for projects under construction, business development (income) expenses for expansion into new markets, change in fair value of earn-out liabilities, stock-based consideration and personnel non-recurring compensation.
Segment Adjusted EBITDA Margin: is calculated as segment Adjusted EBITDA divided by total Segment revenue from contracts with customers.
15
Segment Adjusted EBITDA Margin
(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)
| 3Q'26 | Δ 3Q'26 vs | Δ YTD 26 vs | ||||||||||||||||||||||
| (USD) | 3Q'26 | YTD 26 | 3Q'25 | 2Q'26 | YTD 25 | |||||||||||||||||||
| Revenues | 386 | 1,325 | 3,741 | 19 | % | 7 | % | 15 | % | |||||||||||||||
| Profit (Loss) before Tax | 14 | 49 | 124 | -50 | % | -18 | % | -57 | % | |||||||||||||||
| (+) Net Finance Cost | 33 | 112 | 359 | 56 | % | 6 | % | 80 | % | |||||||||||||||
| (+) Depreciation and Amortization | 18 | 61 | 178 | 7 | % | 5 | % | 7 | % | |||||||||||||||
| (=) EBITDA | 65 | 222 | 660 | -2 | % | 0 | % | 1 | % | |||||||||||||||
| (+) Adjustments | 2.7 | 9.2 | 15.3 | |||||||||||||||||||||
| (a) Pre-operating expenses | 0.1 | 0.3 | 0.7 | |||||||||||||||||||||
| (b) Business development expenses | 1.5 | 5.2 | 6.0 | |||||||||||||||||||||
| (c) Stock-based consideration | 1.1 | 3.7 | 8.5 | |||||||||||||||||||||
| (d) Personnel non-recurring compensation | 0.0 | 0.0 | 0.0 | |||||||||||||||||||||
| (=) Adjusted EBITDA | 67 | 231 | 676 | 0 | % | 2 | % | -3 | % | |||||||||||||||
| Adjusted EBITDA Margin | 17.5 | % | 18.1% | -3.3 p.p. | -0.9 p.p. | -3.3 p.p. | ||||||||||||||||||
(a) Pre-operating expenses consist of legal and administrative expenses incurred in connection with medical facilities under construction, such as Clínica Chiclayo, costs relating to the Centro Ambulatorio Trecca PPP, and legal and administrative expenses incurred in connection with the acquisition of land banks for future facilities.
(b) Business development expenses consist of expenses incurred in connection with projects and payments to sellers to expand into new markets, including through greenfield projects and M&A activity.
(c) Stock-based consideration includes share-based payments plans for non-executive members of the Board of Directors and other Auna management including executives and employees.
(d) Personnel non-recurring compensation related to the implementation of an efficiency program across business units aimed at streamlining processes and capturing synergies on the local and regional levels.
Segment Adjusted EBITDA Margin
For the three months ended September 30, 2026
| Healthcare Services Mexico | Healthcare Services Peru | Oncosalud Peru | Healthcare Services Colombia | Holding and eliminations | Consolidated Reportable Segments | |||||||||||||||||||
| Revenues | 316 | 307 | 323 | 494 | (115 | ) | 1,325 | |||||||||||||||||
| Profit (Loss) before Tax | 11 | 21 | 53 | 15 | (52 | ) | 49 | |||||||||||||||||
| (+) Net Finance Cost | 41 | 4 | 4 | 14 | 49 | 112 | ||||||||||||||||||
| (+) Depreciation and Amortization | 24 | 11 | 10 | 14 | 3 | 61 | ||||||||||||||||||
| (=) Segment EBITDA | 76 | 36 | 67 | 43 | 0 | 222 | ||||||||||||||||||
| (+) Adjustments | 7.3 | 0.4 | 0.4 | 0.2 | 0.8 | 9.2 | ||||||||||||||||||
| Pre-operating expenses | 0.1 | 0.0 | 0.0 | 0.0 | 0.3 | 0.3 | ||||||||||||||||||
| Business development expenses | 5.2 | 0.0 | 0.0 | 0.0 | 0.0 | 5.2 | ||||||||||||||||||
| Stock-based consideration | 2.1 | 0.4 | 0.4 | 0.2 | 0.6 | 3.7 | ||||||||||||||||||
| Personnel non-recurring compensation | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ||||||||||||||||||
| (=) Segment Adjusted EBITDA | 83 | 37 | 68 | 43 | 1 | 231 | ||||||||||||||||||
| Adjusted EBITDA Margin | 26.3 | % | 11.9 | % | 20.9 | % | 8.8 | % | 17.5 | % | ||||||||||||||
16
For the three months ended September 30, 2025
| Healthcare Services Mexico | Healthcare Services Peru | Oncosalud Peru | Healthcare Services Colombia | Holding and eliminations | Consolidated Reportable Segments | |||||||||||||||||||
| Revenues | 264 | 279 | 294 | 369 | (88 | ) | 1,117 | |||||||||||||||||
| Profit (Loss) before Tax | 21 | 20 | 54 | 33 | (31 | ) | 97 | |||||||||||||||||
| (+) Net Finance Cost | 33 | 9 | 3 | 6 | 21 | 72 | ||||||||||||||||||
| (+) Depreciation and Amortization | 22 | 12 | 9 | 11 | 3 | 57 | ||||||||||||||||||
| (=) Segment EBITDA | 76 | 42 | 65 | 49 | (7 | ) | 226 | |||||||||||||||||
| (+) Adjustments | 0.9 | 1.8 | 1.8 | 1.8 | 0.3 | 6.6 | ||||||||||||||||||
| Pre-operating expenses | 0.0 | 0.0 | 0.0 | 0.0 | -0.3 | -0.3 | ||||||||||||||||||
| Business development expenses | -1.0 | 1.6 | 1.6 | 1.7 | 0.0 | 3.8 | ||||||||||||||||||
| Stock-based consideration | 1.9 | 0.2 | 0.2 | 0.1 | 0.6 | 3.0 | ||||||||||||||||||
| Personnel non-recurring compensation | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ||||||||||||||||||
| (=) Segment Adjusted EBITDA | 77 | 44 | 67 | 51 | (6 | ) | 232 | |||||||||||||||||
| Adjusted EBITDA Margin | 29.0 | % | 15.7 | % | 22.9 | % | 13.9 | % | 20.8 | % | ||||||||||||||
Year to date September 30, 2026
| Healthcare Services Mexico | Healthcare Services Peru | Oncosalud Peru | Healthcare Services Colombia | Holding and eliminations | Consolidated Reportable Segments | |||||||||||||||||||
| Revenues | 895 | 885 | 954 | 1,321 | (314 | ) | 3,741 | |||||||||||||||||
| Profit (Loss) before Tax | 22 | 54 | 154 | 80 | (186 | ) | 124 | |||||||||||||||||
| (+) Net Finance Cost | 131 | 15 | 17 | 27 | 169 | 359 | ||||||||||||||||||
| (+) Depreciation and Amortization | 70 | 32 | 31 | 36 | 8 | 178 | ||||||||||||||||||
| (=) Segment EBITDA | 223 | 102 | 202 | 144 | (10 | ) | 660 | |||||||||||||||||
| (+) Adjustments | 11.7 | 0.4 | 0.6 | 0.3 | 2.4 | 15.3 | ||||||||||||||||||
| Pre-operating expenses | 0.1 | 0.0 | 0.0 | 0.0 | 0.6 | 0.7 | ||||||||||||||||||
| Business development expenses | 6.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6.0 | ||||||||||||||||||
| Stock-based consideration | 5.5 | 0.4 | 0.6 | 0.3 | 1.7 | 8.5 | ||||||||||||||||||
| Personnel non-recurring compensation | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ||||||||||||||||||
| (=) Segment Adjusted EBITDA | 234 | 102 | 202 | 145 | -7 | 676 | ||||||||||||||||||
| Adjusted EBITDA Margin | 26.2 | % | 11.5 | % | 21.2 | % | 10.9 | % | 18.1 | % | ||||||||||||||
Year to date September 30, 2025
| Healthcare Services Mexico | Healthcare Services Peru | Oncosalud Peru | Healthcare Services Colombia | Holding and eliminations | Consolidated Reportable Segments | |||||||||||||||||||
| Revenues | 781 | 812 | 861 | 1,054 | (253 | ) | 3,253 | |||||||||||||||||
| Profit (Loss) before Tax | 41 | 54 | 152 | 105 | (62 | ) | 291 | |||||||||||||||||
| (+) Net Finance Cost | 106 | 27 | 13 | 13 | 39 | 199 | ||||||||||||||||||
| (+) Depreciation and Amortization | 65 | 36 | 27 | 31 | 8 | 166 | ||||||||||||||||||
| (=) Segment EBITDA | 212 | 117 | 192 | 148 | (15 | ) | 655 | |||||||||||||||||
| (+) Adjustments | 32.5 | 2.1 | 2.1 | 1.9 | 2.2 | 40.9 | ||||||||||||||||||
| Pre-operating expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.4 | 0.4 | ||||||||||||||||||
| Business development expenses | 26.6 | 1.6 | 1.6 | 1.7 | 0.0 | 31.5 | ||||||||||||||||||
| Stock-based consideration | 5.3 | 0.5 | 0.5 | 0.2 | 1.8 | 8.3 | ||||||||||||||||||
| Personnel non-recurring compensation | 0.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.6 | ||||||||||||||||||
| (=) Segment Adjusted EBITDA | 245 | 119 | 194 | 150 | -13 | 696 | ||||||||||||||||||
| Adjusted EBITDA Margin | 31.4 | % | 14.7 | % | 22.6 | % | 14.3 | % | 21.4 | % | ||||||||||||||
Consolidated Peru Adjusted EBITDA: is calculated by adding Healthcare Services Peru segment Adjusted EBITDA plus Oncosalud Peru segment Adjusted EBITDA.
Consolidated Peru Adjusted EBITDA Margin: is calculated as Healthcare Services Peru segment Adjusted EBITDA plus Oncosalud Peru segment Adjusted EBITDA, divided by total revenues from Healthcare Services Peru Segment plus total revenues from Oncosalud Peru segment, net of inter-segment eliminations.
17
Adjusted Net Income: is calculated as profit (loss) for the period plus adjustments as described below.
Adjusted Net Income
(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)
| 3Q'26 (USD) | 3Q'26 | 3Q'25 | YTD 26 | YTD 25 | ||||||||||||||||
| Net Income (Loss) | 7 | 24 | 53 | 67 | 175 | |||||||||||||||
| (a) Pre-operating expenses | 0.1 | 0.3 | (0.3 | ) | 0.7 | 0.4 | ||||||||||||||
| (b) Business development expenses | 1.5 | 5.2 | 3.8 | 6.0 | 31.5 | |||||||||||||||
| (c) Stock-based consideration | 1.1 | 3.7 | 3.0 | 8.5 | 8.3 | |||||||||||||||
| (d) Personnel non-recurring compensation | 0.0 | 0.0 | 0.0 | 0.0 | 0.6 | |||||||||||||||
| (e) Non-cash and non-recurring financial costs | 1.6 | 5.6 | 1.1 | 16.4 | 1.1 | |||||||||||||||
| (f) Allocated tax effects | (1.4 | ) | (4.8 | ) | (3.0 | ) | (7.5 | ) | (16.0 | ) | ||||||||||
| (=) Adjusted Net Income | 10 | 35 | 58 | 91 | 201 | |||||||||||||||
(a) Pre-operating expenses consist of legal and administrative expenses incurred in connection with medical facilities under construction, such as Clínica Chiclayo, costs relating to the Centro Ambulatorio Trecca PPP, and legal and administrative expenses incurred in connection with the acquisition of land banks for future facilities.
(b) Business development expenses consist of expenses incurred in connection with projects and payments to sellers to expand into new markets, including through greenfield projects and M&A activity.
(c) Stock-based consideration includes share-based payments plans for non-executive members of the Board of Directors and other Auna management including executives and employees.
(d) Personnel non-recurring compensation related to the implementation of an efficiency program across business units aimed at streamlining processes and capturing synergies on the local and regional levels.
(e) Non-cash and non-recurring financial costs include: 1) non-cash effects related to the accounting impact of changes in the fair value of the liability for mandatory purchase of shares from IMAT; and 2) withholding tax expenses associated with financing and refinancing activities.
(f) Allocated tax effects neutralize the tax shield that the items considered as adjustment have generated in the taxable profit.
Basic and Diluted Earnings per Share: Basic and Diluted Earnings per Share is calculated by dividing the profit attributable to owners of the Company by the weighted average number of basic and diluted shares outstanding during the period, which excludes treasury shares.
Adjusted Basic and Diluted Earnings per Share: Adjusted Basic and Diluted Earnings per Share is calculated by dividing profit attributable to owners of Adjusted Net Income of the Company by the weighted average number of basic and diluted shares outstanding during the period, which excludes treasury shares.
18
Adjusted Basic and Diluted Earnings per Share
(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)
| 3Q'26 (USD) | 3Q'26 | 3Q'25 | YTD 26 | YTD 25 | ||||||||||||||||
| Net Income (Loss) | 7 | 24 | 53 | 67 | 175 | |||||||||||||||
| Income (Loss) attributable to Owner of the company | 6 | 20 | 48 | 56 | 166 | |||||||||||||||
| Weighted average number of basic and diluted shares at September 30 | 74.2 | 74.2 | 74.2 | 74.2 | ||||||||||||||||
| Basic and diluted earnings per share | 0.08 | 0.27 | 0.65 | 0.76 | 2.23 | |||||||||||||||
| Adjusted Net Income (Loss) | 10 | 35 | 58 | 91 | 201 | |||||||||||||||
| Income (Loss) attributable to owners of Adjusted Net Income | 9 | 30 | 53 | 81 | 191 | |||||||||||||||
| Weighted average number of basic and diluted shares at September 30 | 74.2 | 74.2 | 74.2 | 74.2 | ||||||||||||||||
| Adjusted Basic and Diluted Earnings per Share | 0.12 | 0.41 | 0.71 | 1.09 | 2.58 | |||||||||||||||
Leverage Ratio: We calculate Leverage Ratio as (i) current and non-current loans and borrowings plus current and non-current lease liabilities minus (ii) cash and cash equivalents, divided by (iii) Adjusted Last Twelve Months EBITDA.
Leverage Ratio
(Figures in millions of Soles, unless expressed otherwise)
| Sep-25 | Dec-25 | Sep-26 | ||||||||||
| Current and non-current loans & borrowings | 3,526 | 3,533 | 3,600 | |||||||||
| Current and non-current lease liabilities | 129 | 124 | 146 | |||||||||
| Cash and cash equivalents | 226 | 335 | 614 | |||||||||
| Net Debt | 3,429 | 3,321 | 3,133 | |||||||||
| Adjusted LTM EBITDA | 951 | 917 | 896 | |||||||||
| Leverage Ratio | 3.6 | x | 3.6 | x | 3.5 | x | ||||||
Net Debt: We calculate Net Debt as Gross Debt minus Cash and cash equivalents.
Net Debt
(Figures in millions of Soles, unless expressed otherwise)
| Sep-25 | Dec-25 | Sep-26 | ||||||||||
| (+) Loans and borrowings | 3,526 | 3,533 | 3,600 | |||||||||
| Short term debt | 658 | 316 | 465 | |||||||||
| Long term debt | 2,868 | 3,216 | 3,136 | |||||||||
| (+) Lease Liabilities | 129 | 124 | 146 | |||||||||
| Gross Debt | 3,655 | 3,656 | 3,746 | |||||||||
| (-) Cash and cash equivalents | 226 | 335 | 614 | |||||||||
| Net Debt | 3,429 | 3,321 | 3,133 | |||||||||
19
Free Cash Flow: is calculated by adding Net Cash Flows from Operations and Net Cash Flows used in Investing activities.
Free Cash Flow Reconciliation
(Figures in millions of Soles, unless expressed otherwise)
| Sep-25 | Sep-26 | |||||||
| Cash generated from operating activities | 582 | 753 | ||||||
| (-) Income tax | 155 | 54 | ||||||
| (+) Interest received | 13 | 14 | ||||||
| Net cash from operating activities | 440 | 713 | ||||||
| Net cash used in investing activities | (119 | ) | (86 | ) | ||||
| Free Cash Flow | 321 | 626 | ||||||
FX Neutral: FX Neutral (“FXN”) measures are prepared and presented to eliminate the effect of foreign exchange, or “FX,” volatility between the comparison periods, allowing management and investors to evaluate financial performance despite variations in foreign currency exchange rates, which may not be indicative of core operating results and business outlook.
FX Neutral measures are presented because management believes that these non-IFRS financial measures can provide useful information to investors, securities analysts and the public in their review of operating and financial performance, although they are not calculated in accordance with IFRS or any other generally accepted accounting principles and should not be considered as a measure of performance in isolation.
The FX Neutral measures were calculated to present what such measures in preceding periods would have been had exchange rates remained stable from these preceding periods until the date of the Company’s most recent financial information.
The FX Neutral measures for the three months ended September 30, 2025 were calculated by multiplying the as reported amounts of Revenue, Adjusted EBITDA and the key business metrics for such period by the average Mexican pesos / Peruvian soles exchange rate for the three months ended September 30, 2025 (MXN 5.2713 to PEN 1.00) and the average Colombian pesos / Peruvian soles exchange rate for the three months ended September 30, 2025 (COP 1,131.3043 to PEN 1.00); then using such results to re-translate the corresponding amounts back to Peruvian soles by dividing them by the average Mexican pesos / Peruvian soles and Colombian pesos / Peruvian soles exchange rate for the three months ended September 30, 2026 (MXN 5.1038 to PEN 1.00 / COP 943.2503 to PEN 1.00), so as to present what certain of statement of profit and loss amounts and key business metrics would have been had exchange rates remained stable from this past period until the three months ended September 30, 2026.
20
Safe Harbor Statement
This press release contains forward-looking statements. Forward-looking statements convey our current expectations or forecasts of future events. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to differ materially from the forward-looking statements that we make. Forward-looking statements typically are identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “project,” “plan,” “believe,” “potential,” “continue,” “is/are likely to,” or other similar expressions. Forward-looking statements that appear in a number of places in this press release include, but are not limited to, statements regarding the intent, belief or current expectations, regarding various matters, including, our target Leverage Ratio, the results of the key initiatives we are implementing in Mexico, Colombia and Peru, the execution of our strategic plan, including the recovery of our growth levels, our planned investments, our revenue, Adjusted EBITDA and capital expenditure guidance, our expectation for revenue and Adjusted EBITDA growth, the timeline for the construction and commencement of operations at the Centro Ambulatorio Trecca in Lima and our ability to recover any loss under the oncology risk-sharing contract in Colombia. Any or all of our forward-looking statements in this press release may turn out to be inaccurate. Our actual results could differ materially from those contained in forward-looking statements due to a number of factors.
The forward-looking statements in this press release represent our expectations and forecasts as of the date of this press release. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release. For a discussion of the risks facing the Company which could affect whether these forward-looking statements are realized, see our Form 20-F filing with the U.S. Securities and Exchange Commission (the “SEC”).
Financial Guidance Disclaimer
Auna′s guidance is based on management’s current performance outlook and expected macroeconomic and regulatory conditions in the three countries where the Company operates. Any changes in these conditions could have an impact on the guidance provided.
Auna’s financial guidance reflects management’s current assumptions regarding numerous evolving factors that are difficult to accurately predict, including those discussed in the Risk Factors set forth in the Company’s Form 20-F filed with the SEC. Reconciliations of forward-looking non-IFRS measures, specifically the Leverage Ratio target and Adjusted EBITDA guidance, to the relevant forward-looking IFRS measures are not being provided, as the Company does not currently have sufficient data to accurately estimate the variables and individual adjustments for such guidance and reconciliations. Due to this uncertainty, the Company cannot reconcile projected Adjusted EBITDA to projected net income without unreasonable effort. The financial guidance constitutes forward-looking statements. For more information, see the “Safe Harbor Statement” section in this release.
21
IR Contact
Email: contact@aunainvestors.com
- Financial Tables Follow –
22
Balance Sheet (1/2)
(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)
Sep-26 (USD) | Sep-26 | Dec-25 | Δ Sep-26 vs Dec-25 | |||||||||||||
| Assets | ||||||||||||||||
| Current assets | ||||||||||||||||
| Cash and cash equivalents | 179 | 614 | 335 | 278 | ||||||||||||
| Trade accounts receivable | 345 | 1,185 | 1,043 | 143 | ||||||||||||
| Other assets | 61 | 211 | 259 | (48 | ) | |||||||||||
| Inventories | 46 | 158 | 165 | (7 | ) | |||||||||||
| Insurance contract assets | — | — | 13 | (13 | ) | |||||||||||
| Other investments | 1 | 3 | 30 | (27 | ) | |||||||||||
| Total current assets | 632 | 2,171 | 1,845 | 326 | ||||||||||||
| Non-current assets | ||||||||||||||||
| Trade accounts receivable | 0 | 0 | 0 | (0 | ) | |||||||||||
| Other assets | 9 | 30 | 27 | 3 | ||||||||||||
| Investments in associates and joint venture | 10 | 35 | 30 | 5 | ||||||||||||
| Property furniture and equipment | 701 | 2,405 | 2,287 | 118 | ||||||||||||
| Intangible assets | 824 | 2,829 | 2,704 | 125 | ||||||||||||
| Right-of-use assets | 38 | 131 | 113 | 18 | ||||||||||||
| Investment properties | 2 | 7 | 6 | 0 | ||||||||||||
| Derivative financial instruments | 16 | 56 | 54 | 2 | ||||||||||||
| Deferred tax assets | 82 | 282 | 231 | 52 | ||||||||||||
| Other investments | 0 | 1 | 1 | (0 | ) | |||||||||||
| Total non-current assets | 1,683 | 5,776 | 5,454 | 323 | ||||||||||||
| Total assets | 2,315 | 7,947 | 7,298 | 649 | ||||||||||||
23
Balance Sheet (2/2)
(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)
Sep-26 (USD) | Sep-26 | Dec-25 | Δ Sep-26 vs Dec-25 | |||||||||||||
| Liabilities | ||||||||||||||||
| Current liabilities | ||||||||||||||||
| Loans and borrowings | 135 | 465 | 316 | 148 | ||||||||||||
| Lease liabilities | 10 | 34 | 29 | 5 | ||||||||||||
| Trade accounts payable | 348 | 1,196 | 1,053 | 143 | ||||||||||||
| Other accounts payable | 85 | 291 | 225 | 65 | ||||||||||||
| Provisions | 4 | 13 | 10 | 3 | ||||||||||||
| Derivative financial instruments | 8 | 28 | 23 | 5 | ||||||||||||
| Insurance contract liabilities | 5 | 18 | 9 | 9 | ||||||||||||
| Deferred income | 0 | 1 | 0 | 0 | ||||||||||||
| Total current liabilities | 596 | 2,046 | 1,667 | 379 | ||||||||||||
| Non-current liabilities | ||||||||||||||||
| Loans and borrowings | 913 | 3,136 | 3,216 | (80 | ) | |||||||||||
| Lease liabilities | 33 | 112 | 94 | 18 | ||||||||||||
| Trade accounts payable | 0 | 0 | 1 | (1 | ) | |||||||||||
| Other accounts payable | 69 | 236 | 222 | 14 | ||||||||||||
| Derivative financial instruments | 6 | 21 | 40 | (18 | ) | |||||||||||
| Deferred tax liabilities | 80 | 276 | 291 | (15 | ) | |||||||||||
| Deferred income | 0 | 1 | 0 | 1 | ||||||||||||
| Total non-current liabilities | 1,102 | 3,783 | 3,865 | (82 | ) | |||||||||||
| Total liabilities | 1,698 | 5,828 | 5,532 | 297 | ||||||||||||
| Total equity | 617 | 2,119 | 1,766 | 352 | ||||||||||||
| Total liabilities and equity | 2,315 | 7,947 | 7,298 | 649 |
24
Income Statement
(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)
3Q'26 (USD) | 3Q'26 | YTD 26 | Δ 3Q'26 vs 3Q'25 | Δ YTD 26 vs YTD 25 | ||||||||||||||||
| Revenue | ||||||||||||||||||||
| Healthcare Services Mexico | 92 | 316 | 895 | 20 | % | 15 | % | |||||||||||||
| Healthcare Services Colombia | 144 | 493 | 1,318 | 35 | % | 26 | % | |||||||||||||
| - Healthcare Services Colombia | 144 | 494 | 1,321 | 34 | % | 25 | % | |||||||||||||
| - Holding and eliminations | (0 | ) | (1 | ) | (4 | ) | -74 | % | -4 | % | ||||||||||
| Healthcare Services Peru & Oncosalud Peru | 150 | 516 | 1,528 | 6 | % | 7 | % | |||||||||||||
| - Healthcare Services Peru | 89 | 307 | 885 | 10 | % | 9 | % | |||||||||||||
| - Oncosalud Peru | 94 | 323 | 954 | 10 | % | 11 | % | |||||||||||||
| - Holding and eliminations | (33 | ) | (114 | ) | (310 | ) | 35 | % | 24 | % | ||||||||||
| Total Revenue | 386 | 1,325 | 3,741 | 19 | % | 15 | % | |||||||||||||
| Cost of sales and services | (256 | ) | (879 | ) | (2,421 | ) | 26 | % | 20 | % | ||||||||||
| Gross profit | 130 | 446 | 1,319 | 6 | % | 7 | % | |||||||||||||
| Gross margin | 33.7 | % | 35.3 | % | -3.9 p.p. | -2.7 p.p. | ||||||||||||||
| Selling expenses | (18 | ) | (62 | ) | (186 | ) | 5 | % | 12 | % | ||||||||||
| Administrative expenses | (68 | ) | (232 | ) | (678 | ) | 16 | % | 15 | % | ||||||||||
| (Loss) reversal for impairment of trade receivables | (1 | ) | (3 | ) | (11 | ) | -48 | % | -62 | % | ||||||||||
| Other income and expenses, net | 3 | 10 | 31 | -13 | % | -4 | % | |||||||||||||
| Operating profit | 46 | 158 | 475 | -4 | % | -1 | % | |||||||||||||
| Finance income | 2 | 7 | 15 | 63 | % | -1 | % | |||||||||||||
| Finance income from exchange difference | 0 | 0 | 0 | -100 | % | -100 | % | |||||||||||||
| Finance costs | (35 | ) | (119 | ) | (355 | ) | 3 | % | -1 | % | ||||||||||
| Finance costs from exchange difference | — | — | (19 | ) | — | — | ||||||||||||||
| Net finance cost | (33 | ) | (112 | ) | (359 | ) | 56 | % | 80 | % | ||||||||||
| Share of profit of equity accounted investees | 1 | 3 | 8 | -8 | % | -5 | % | |||||||||||||
| Profit (loss) before tax | 14 | 49 | 124 | -50 | % | -57 | % | |||||||||||||
| Income tax expense (benefit) | (7 | ) | (24 | ) | (58 | ) | -45 | % | -50 | % | ||||||||||
| Net Income (Loss) | 7 | 24 | 67 | -54 | % | -62 | % | |||||||||||||
| EBITDA | ||||||||||||||||||||
| Healthcare Services Mexico | 22 | 76 | 223 | 0 | % | 5 | % | |||||||||||||
| Healthcare Services Colombia | 13 | 43 | 144 | -13 | % | -3 | % | |||||||||||||
| Healthcare Services Peru & Oncosalud Peru | 30 | 103 | 303 | -4 | % | -2 | % | |||||||||||||
| - Healthcare Services Peru | 11 | 36 | 102 | -14 | % | -13 | % | |||||||||||||
| - Oncosalud Peru | 20 | 67 | 202 | 2 | % | 5 | % | |||||||||||||
| Holding and eliminations | 0 | 0 | (10 | ) | ||||||||||||||||
| Total EBITDA | 65 | 222 | 660 | -2 | % | 1 | % | |||||||||||||
| Adjusted EBITDA | ||||||||||||||||||||
| Healthcare Services Mexico | 24 | 83 | 234 | 8 | % | -4 | % | |||||||||||||
| Healthcare Services Colombia | 13 | 43 | 145 | -16 | % | -4 | % | |||||||||||||
| Healthcare Services Peru & Oncosalud Peru | 30 | 104 | 304 | -6 | % | -3 | % | |||||||||||||
| - Healthcare Services Peru | 11 | 37 | 102 | -16 | % | -15 | % | |||||||||||||
| - Oncosalud Peru | 20 | 68 | 202 | 0 | % | 4 | % | |||||||||||||
| Holding and eliminations | 0 | 1 | (7 | ) | ||||||||||||||||
| Total Adjusted EBITDA | 67 | 231 | 676 | 0 | % | -3 | % | |||||||||||||
| Adjusted EBITDA Margin | ||||||||||||||||||||
| Healthcare Services Mexico | 26.3 | % | 26.2 | % | -2.7 p.p. | -5.2 p.p. | ||||||||||||||
| Healthcare Services Colombia | 8.8 | % | 10.9 | % | -5.1 p.p. | -3.3 p.p. | ||||||||||||||
| Healthcare Services Peru & Oncosalud Peru | 20.2 | % | 19.9 | % | -2.6 p.p. | -2.1 p.p. | ||||||||||||||
| - Healthcare Services Peru | 11.9 | % | 11.5 | % | -3.8 p.p. | -3.2 p.p. | ||||||||||||||
| - Oncosalud Peru | 20.9 | % | 21.2 | % | -2.0 p.p. | -1.4 p.p. | ||||||||||||||
| Adjusted EBITDA Margin | 17.5 | % | 18.1 | % | -3.3 p.p. | -3.3 p.p. |
25
Statement of Cash Flows (1/2)
(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)
| YTD 26 (USD) | YTD 26 | YTD 25 | Δ YTD 26 vs YTD 25 | |||||||||||||
| Cash flows from operating activities | ||||||||||||||||
| (Loss) profit for the period | 19 | 67 | 175 | (108 | ) | |||||||||||
| Adjustments for: | ||||||||||||||||
| Depreciation | 27 | 91 | 86 | 5 | ||||||||||||
| Depreciation of right-of-use assets | 6 | 22 | 21 | 1 | ||||||||||||
| Amortization | 19 | 64 | 59 | 5 | ||||||||||||
| (Reversal) Impairment of inventories | 0 | 1 | 0 | 0 | ||||||||||||
| Equity-settled share-based payment transactions | 2 | 9 | 8 | 0 | ||||||||||||
| Gain (loss) on disposal of property furniture and equipment | 0 | 0 | (1 | ) | 2 | |||||||||||
| Loss on disposal of right-of-use assets net of leases | — | — | (0 | ) | 0 | |||||||||||
| (Reversal) loss for impairment of trade receivables | 3 | 11 | 29 | (18 | ) | |||||||||||
| Share of profit of equity-accounted investees | (2 | ) | (8 | ) | (8 | ) | 0 | |||||||||
| Technical provisions and other provisions | 1 | 5 | 1 | 4 | ||||||||||||
| Finance income | (4 | ) | (15 | ) | (161 | ) | 145 | |||||||||
| Finance costs | 109 | 374 | 359 | 15 | ||||||||||||
| Tax expense | 17 | 58 | 116 | (58 | ) | |||||||||||
| Net changes in assets and liabilities | ||||||||||||||||
| Trade accounts receivable and other assets | (21 | ) | (72 | ) | (132 | ) | 60 | |||||||||
| Inventories | 5 | 19 | (1 | ) | 20 | |||||||||||
| Trade accounts payable and other accounts payable | 32 | 109 | 35 | 73 | ||||||||||||
| Provisions and employee benefits | (1 | ) | (2 | ) | (4 | ) | 1 | |||||||||
| Insurance contract liabilities | 6 | 22 | (1 | ) | 23 | |||||||||||
| Cash generated from operating activities | 219 | 753 | 582 | 171 | ||||||||||||
| Income tax paid | (16 | ) | (54 | ) | (155 | ) | 101 | |||||||||
| Interest received | 4 | 14 | 13 | 0 | ||||||||||||
| Net cash from operating activities | 208 | 713 | 440 | 273 | ||||||||||||
26
Statement of Cash Flows (2/2)
(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)
| YTD 26 (USD) | YTD 26 | YTD 25 | Δ YTD 26 vs YTD 25 | |||||||||||||
| Cash flows from investing activities | ||||||||||||||||
| Payment for accounts payables to former shareholder | (2 | ) | (6 | ) | (21 | ) | 14 | |||||||||
| Purchase of properties furniture and equipment | (21 | ) | (71 | ) | (66 | ) | (4 | ) | ||||||||
| Purchase of intangibles | (12 | ) | (41 | ) | (47 | ) | 6 | |||||||||
| Dividends from equity-accounted investees | 1 | 2 | 3 | (1 | ) | |||||||||||
| Purchase of other investments, net of sales | 8 | 29 | 5 | 24 | ||||||||||||
| Proceeds from sale of property furniture and equipment | 0 | 0 | 6 | (6 | ) | |||||||||||
| Net cash used in investing activities | (25 | ) | (86 | ) | (119 | ) | 33 | |||||||||
| Cash flows from financing activities | ||||||||||||||||
| Proceeds from settlement of derivatives - interest rate swaps | (6 | ) | (19 | ) | (9 | ) | (10 | ) | ||||||||
| Proceeds from loans and borrowings | 82 | 282 | 1,079 | (797 | ) | |||||||||||
| Payment for loans and borrowings | (102 | ) | (349 | ) | (1,084 | ) | 735 | |||||||||
| Payment for lease liabilities | (10 | ) | (34 | ) | (34 | ) | (0 | ) | ||||||||
| Penalty paid for debt prepayment | (0 | ) | (0 | ) | (0 | ) | (0 | ) | ||||||||
| Payment for derivatives premiums | (4 | ) | (15 | ) | (17 | ) | 2 | |||||||||
| Interest paid | (66 | ) | (228 | ) | (271 | ) | 43 | |||||||||
| Net cash used in financing activities | (106 | ) | (363 | ) | (336 | ) | (27 | ) | ||||||||
| Net (decrease) increase in cash and cash equivalents | 77 | 263 | (15 | ) | 279 | |||||||||||
| Cash and cash equivalents at January 1 | 98 | 335 | 236 | 100 | ||||||||||||
| Effect of movements in exchange rates on cash held | 4 | 15 | 5 | 10 | ||||||||||||
| Cash and cash equivalents at the end of the period | 179 | 614 | 226 | 388 | ||||||||||||
27
Historical Financial Metrics
(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)
| 3Q'24 | 4Q'24 | 1Q'25 | 2Q'25 | 3Q'25 | 4Q'25 | 1Q'26 | 2Q'26 | 3Q'26 | ||||||||||||||||||||||||||||
| Revenue | ||||||||||||||||||||||||||||||||||||
| Oncosalud Peru | 273 | 276 | 281 | 286 | 294 | 304 | 314 | 317 | 323 | |||||||||||||||||||||||||||
| Healthcare Services Peru | 255 | 245 | 263 | 269 | 279 | 273 | 281 | 296 | 307 | |||||||||||||||||||||||||||
| Healthcare Services Colombia | 363 | 353 | 339 | 346 | 369 | 387 | 400 | 427 | 494 | |||||||||||||||||||||||||||
| Healthcare Services Mexico | 316 | 268 | 243 | 274 | 264 | 258 | 279 | 300 | 316 | |||||||||||||||||||||||||||
| Holding and eliminations | (80 | ) | (79 | ) | (84 | ) | (81 | ) | (88 | ) | (89 | ) | (96 | ) | (103 | ) | (115 | ) | ||||||||||||||||||
| Total revenue from contracts with customers | 1,127 | 1,063 | 1,042 | 1,094 | 1,117 | 1,133 | 1,178 | 1,238 | 1,325 | |||||||||||||||||||||||||||
| Cost of sales and services | (677 | ) | (629 | ) | (660 | ) | (660 | ) | (698 | ) | (704 | ) | (747 | ) | (796 | ) | (879 | ) | ||||||||||||||||||
| Gross profit | 449 | 434 | 382 | 434 | 419 | 429 | 431 | 442 | 446 | |||||||||||||||||||||||||||
| Selling expenses | (55 | ) | (42 | ) | (54 | ) | (54 | ) | (59 | ) | (54 | ) | (62 | ) | (62 | ) | (62 | ) | ||||||||||||||||||
| Administrative expenses | (195 | ) | (201 | ) | (182 | ) | (208 | ) | (200 | ) | (222 | ) | (214 | ) | (232 | ) | (232 | ) | ||||||||||||||||||
| Impairment losses on trade receivables | (25 | ) | (13 | ) | (16 | ) | (8 | ) | (5 | ) | (19 | ) | (9 | ) | 0 | (3 | ) | |||||||||||||||||||
| Other expenses | 0 | (2 | ) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||
| Other income | 54 | 14 | 9 | 12 | 11 | 11 | 9 | 13 | 10 | |||||||||||||||||||||||||||
| Operating profit | 229 | 190 | 139 | 176 | 166 | 144 | 155 | 162 | 158 | |||||||||||||||||||||||||||
| Finance income | 6 | 7 | 6 | 5 | 4 | 6 | 4 | 5 | 7 | |||||||||||||||||||||||||||
| Finance income from exchange difference | 28 | (31 | ) | 37 | 68 | 40 | 48 | 0 | 0 | 0 | ||||||||||||||||||||||||||
| Finance costs | (138 | ) | (138 | ) | (123 | ) | (120 | ) | (116 | ) | (292 | ) | (118 | ) | (118 | ) | (119 | ) | ||||||||||||||||||
| Finance costs from exchange difference | 0 | 8 | 0 | 0 | 0 | 0 | (26 | ) | 8 | 0 | ||||||||||||||||||||||||||
| Net finance cost | (103 | ) | (155 | ) | (80 | ) | (46 | ) | (72 | ) | (238 | ) | (141 | ) | (105 | ) | (112 | ) | ||||||||||||||||||
| Share of profit of equity-accounted investees | 2 | 2 | 3 | 2 | 3 | 2 | 3 | 2 | 3 | |||||||||||||||||||||||||||
| Profit (loss) before tax | 127 | 37 | 62 | 132 | 97 | (91 | ) | 16 | 59 | 49 | ||||||||||||||||||||||||||
| Income tax (expense) benefit | (27 | ) | (13 | ) | (24 | ) | (48 | ) | (44 | ) | 27 | (7 | ) | (26 | ) | (24 | ) | |||||||||||||||||||
| Net Income | 101 | 24 | 38 | 84 | 53 | (64 | ) | 9 | 33 | 24 | ||||||||||||||||||||||||||
| EBITDA | 286 | 244 | 195 | 234 | 226 | 203 | 215 | 223 | 222 | |||||||||||||||||||||||||||
| EBITDA Adjustments | ||||||||||||||||||||||||||||||||||||
| Net Income | 101 | 24 | 38 | 84 | 53 | (64 | ) | 9 | 33 | 24 | ||||||||||||||||||||||||||
| Income tax expense | 27 | 13 | 24 | 48 | 44 | (27 | ) | 7 | 26 | 24 | ||||||||||||||||||||||||||
| Net finance cost | 103 | 155 | 80 | 46 | 72 | 238 | 141 | 105 | 112 | |||||||||||||||||||||||||||
| Depreciation and amortization | 55 | 52 | 53 | 55 | 57 | 56 | 57 | 59 | 61 | |||||||||||||||||||||||||||
| (a) Pre-operating expenses | 0 | 0 | 0 | 0 | (0 | ) | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||
| (b) Business development expenses | (44 | ) | 3 | 24 | 4 | 4 | 10 | 0 | 1 | 5 | ||||||||||||||||||||||||||
| (c) Change in fair value of earn-out liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||
| (d) Stock-based consideration | 6 | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 4 | |||||||||||||||||||||||||||
| (e) Personnel non-recurring compensation | 2 | 5 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | |||||||||||||||||||||||||||
| (f) Change in fair value of investment properties | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||||
| Adjusted EBITDA | 250 | 254 | 222 | 241 | 232 | 220 | 217 | 227 | 231 | |||||||||||||||||||||||||||
28
Key Operating Metrics
| 3Q'26 | YTD 26 | Δ 3Q'26 vs 3Q'25 | Δ YTD 26 vs YTD 25 | |||||||||||||
| Oncosalud Peru | ||||||||||||||||
| Plan memberships (1) (2) | 1,441,794 | 1,441,794 | 3 | % | 3 | % | ||||||||||
| Average monthly revenue per plan member (3) | S/ | 65.15 | S/ | 64.02 | 5 | % | 5 | % | ||||||||
| Preventive check-ups (4) | 25,084 | 81,883 | -14 | % | -13 | % | ||||||||||
| Patients treated (5) | 56,127 | 153,625 | 34 | % | 28 | % | ||||||||||
| Medical loss ratio (6) | 58.7 | % | 4.2 p.p | |||||||||||||
| Healthcare Services | ||||||||||||||||
| Total bed capacity (1)(7) | 2,252 | 2,252 | 1 | % | 1 | % | ||||||||||
| Protected Lives (8) | 3,208,686 | 3,208,686 | 6 | % | 6 | % | ||||||||||
| Surgeries (9) | 23,932 | 67,454 | 12 | % | 7 | % | ||||||||||
| Emergency treatments (10) | 101,257 | 290,540 | 8 | % | 9 | % | ||||||||||
| Chemotherapies & Radiotherapies (11) | 55,439 | 162,888 | 7 | % | 6 | % | ||||||||||
| Total number of days hospitalized (12) | 144,041 | 418,206 | 6 | % | 5 | % | ||||||||||
| Operating capacity utilization (13) | 78.4 | % | 76.7 | % | 3.2 p.p | 2.3 p.p | ||||||||||
| Total capacity utilization (14) | 69.5 | % | 68.0 | % | 3.1 p.p | 2.3 p.p | ||||||||||
| 1) | As of period end. |
| 2) | As reported to the National Superintendence of Health Susalud. Includes Oncology plans and Health plans. Includes active plan members and inactive members. Inactive members are defined as those plan members that have not paid monthly fees due for up to three months. As of September 30, 2026, we had 1,341,825 active members and 99,969 inactive members. |
| 3) | Total revenue for the period corresponding to insurance revenue in the Oncosalud Peru segment divided by the average number of plan members during the period, divided by the number of months in the period. |
| 4) | Preventive check-ups consider Oncosalud and Healthcare plan check-ups, including for Auna Corporate plans, receiving check-ups at the Centro de Bienestar Ambulatorio – CBA (Wellness Center) in Lima and at other facilities in Peru. |
| 5) | Number of individual plan members in Oncosalud and Healthcare plans, including Auna Corporate plans, receiving treatment during the period in Peru. Each plan member is counted once for a trimester, however, might have received multiple instances of treatment throughout the year. |
| 6) | MLR is calculated as (i) claims for medical treatment generated by our prepaid oncology and general healthcare plans plus (ii) technical reserves relating to plan members treated pursuant to such plans, whether at our facilities or third-party facilities, divided by revenue generated by our prepaid oncology and general healthcare plans. |
| 7) | Includes all beds within the Healthcare Network and excludes 109 Oncology beds. |
| 8) | Insured population assigned to Auna under risk-sharing agreements in Colombia. |
| 9) | Number of surgeries includes surgeries, outpatient surgeries and cesarean sections. |
| 10) | Emergency care includes the number of visits in the emergency room and may include several visits per patient. |
29
| 11) | Intravenous chemotherapy and radiotherapy infusions in both inpatient and outpatient care; excludes oral treatments. In Peru, includes sessions across the Healthcare Services Network and Oncosalud Segments. |
| 12) | Total number of days during which any of Auna’s beds were occupied by a hospitalized patient during the period, including ICU. |
| 13) | Operating capacity utilization (Occupancy) is calculated as (i) (x) total number of days in which any of our beds had a hospitalized patient during the period divided by (y) total number of operating beds, times (ii) total number of days during the period. |
| 14) | Total capacity utilization (Occupancy) is calculated as (i) (x) total number of days in which any of our beds had a hospitalized patient during the period divided by (y) total number of beds, times (ii) total number of days during the period. |
30
Exhibit 99.2
Auna S.A. and Subsidiaries
Condensed Consolidated Interim Financial Statements
September 30, 2026
Auna S.A. and Subsidiaries
Condensed Consolidated Interim Financial Statements
September 30, 2026
| Contents | Page |
| Condensed Consolidated Interim Statement of Financial Position | 1 |
| Condensed Consolidated Interim Statement of Profit or Loss and Other | |
| Comprehensive Income | 2 |
| Condensed Consolidated Interim Statement of Changes in Equity | 3 |
| Condensed Consolidated Interim Statement of Cash Flows | 4 |
| Operating Segments | 5 - 10 |
| Auna S.A. and Subsidiaries |
| Condensed Consolidated Interim Statement of Financial Position |
| As of September 30, 2026 and December 31, 2025 |
| In thousands of soles | September 30, 2026 | December 31, 2025 | In thousands of soles | September 30, 2026 | December 31, 2025 | |||||||||||
| Assets | Liabilities | |||||||||||||||
| Current assets | Current liabilities | |||||||||||||||
| Cash and cash equivalents | 613,627 | 335,441 | Loans and borrowings | 464,590 | 316,339 | |||||||||||
| Trade accounts receivable | 1,185,407 | 1042,792 | Lease liabilities | 34,339 | 29,282 | |||||||||||
| Other assets | 210,509 | 258,511 | Trade accounts payable | 1,196,003 | 1,053,395 | |||||||||||
| Inventories | 158,201 | 164,798 | Other accounts payable | 290,817 | 225,465 | |||||||||||
| Other investments | 3,011 | 30,237 | Provisions | 13,407 | 10,161 | |||||||||||
| Insurance contract assets | — | 12,778 | Derivative financial instruments | 27,595 | 22,903 | |||||||||||
| Total current assets | 2,170,755 | 1,844,557 | Insurance contract liabilities | 18,307 | 9,447 | |||||||||||
| Deferred income | 560 | 98 | ||||||||||||||
| Non-current assets | Total current liabilities | 2,045,618 | 1,667,090 | |||||||||||||
| Trade accounts receivable | 423 | 486 | ||||||||||||||
| Other assets | 29,764 | 26,910 | Non-current liabilities | |||||||||||||
| Investments in associates and joint venture | 34,640 | 29,848 | Loans and borrowings | 3,135,770 | 3,216,171 | |||||||||||
| Property, furniture, and equipment | 2,405,495 | 2,287,002 | Lease liabilities | 111,788 | 94,237 | |||||||||||
| Intangible assets | 2,828,954 | 2,704,351 | Trade accounts payable | 431 | 1,450 | |||||||||||
| Right-of-use assets | 130,967 | 113,116 | Other accounts payable | 235,836 | 221,940 | |||||||||||
| Investment properties | 6,726 | 6,340 | Derivative financial instruments | 21,313 | 39,647 | |||||||||||
| Derivative financial instruments | 56,380 | 54,036 | Deferred tax liabilities | 276,306 | 291,086 | |||||||||||
| Deferred tax assets | 282,325 | 230,716 | Deferred income | 1,255 | 87 | |||||||||||
| Other investments | 501 | 702 | Total non-current liabilities | 3,782,699 | 3,864,618 | |||||||||||
| Total non-current assets | 5,776,175 | 5,453,507 | Total liabilities | 5,828,317 | 5,531,708 | |||||||||||
| Equity | ||||||||||||||||
| Share capital | 17,390 | 17,389 | ||||||||||||||
| Share premium | 1,210,778 | 1,209,715 | ||||||||||||||
| Reserves | 809,118 | 566,271 | ||||||||||||||
| Retained losses | (122,739 | ) | (192,615 | ) | ||||||||||||
| Equity attributable to the owner of the Company | 1,914,547 | 1,600,760 | ||||||||||||||
| Non-controlling interest | 204,066 | 165,596 | ||||||||||||||
| Total equity | 2,118,613 | 1,766,356 | ||||||||||||||
| Total assets | 7,946,930 | 7,298,064 | Total liabilities and equity | 7,946,930 | 7,298,064 | |||||||||||
1
| Auna S.A. and Subsidiaries |
| Condensed Consolidated Interim Statement of Profit or Loss and Other Comprehensive Income |
| For the three and nine months ended September 30, 2026 and 2025 |
Three-month period ended September 30 | Nine-month period ended September 30 | |||||||||||||||
| In thousands of soles | 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Revenue | ||||||||||||||||
| Insurance revenue | 309,587 | 285,596 | 911,726 | 837,798 | ||||||||||||
| Healthcare services revenue | 929,145 | 744,365 | 2,574,350 | 2,163,424 | ||||||||||||
| Sale of medicines | 86,267 | 87,011 | 254,673 | 251,557 | ||||||||||||
| Total revenue from contracts with customers | 1,324,999 | 1,116,972 | 3,740,749 | 3,252,779 | ||||||||||||
| Cost of sales and services | (878,922 | ) | (697,849 | ) | (2,421,347 | ) | (2,017,637 | ) | ||||||||
| Gross profit | 446,077 | 419,123 | 1,319,402 | 1,235,142 | ||||||||||||
| Selling expenses | (62,345 | ) | (59,114 | ) | (186,315 | ) | (166,941 | ) | ||||||||
| Administrative expenses | (232,178 | ) | (199,831 | ) | (677,892 | ) | (590,463 | ) | ||||||||
| Loss for impairment of trade receivables | (2,845 | ) | (5,481 | ) | (10,893 | ) | (28,825 | ) | ||||||||
| Other income | 9,506 | 10,918 | 30,827 | 32,236 | ||||||||||||
| Operating profit | 158,215 | 165,615 | 475,129 | 481,149 | ||||||||||||
| Finance income | 6,940 | 4,269 | 15,200 | 15,356 | ||||||||||||
| Finance income from exchange difference | 86 | 39,686 | 86 | 145,202 | ||||||||||||
| Finance costs | (119,180 | ) | (115,730 | ) | (355,289 | ) | (359,232 | ) | ||||||||
| Finance costs from exchange difference | — | — | (18,514 | ) | — | |||||||||||
| Net finance cost | (112,154 | ) | (71,775 | ) | (358,517 | ) | (198,674 | ) | ||||||||
| Share of profit of equity-accounted investees | 2,680 | 2,899 | 7,693 | 8,073 | ||||||||||||
| Profit before tax | 48,741 | 96,739 | 124,305 | 290,548 | ||||||||||||
| Income tax expense | (24,278 | ) | (43,798 | ) | (57,662 | ) | (115,622 | ) | ||||||||
| Profit for the period | 24,463 | 52,941 | 66,643 | 174,926 | ||||||||||||
| Other comprehensive income | ||||||||||||||||
| Items that are or may be reclassified subsequently to profit or loss | ||||||||||||||||
| Cash flow hedges | 11,370 | (4,847 | ) | 14,593 | (36,341 | ) | ||||||||||
| Foreign operations – foreign currency translation differences | 30,612 | 34,507 | 267,114 | 101,750 | ||||||||||||
| Other investments at FVOCI – net change in fair value | 12 | 410 | (173 | ) | 1,036 | |||||||||||
| Income tax | (3,547 | ) | 1,405 | (4,479 | ) | 10,667 | ||||||||||
| Other comprehensive income for the period, net of tax | 38,447 | 31,475 | 277,055 | 77,112 | ||||||||||||
| Total comprehensive income for the period | 62,910 | 84,416 | 343,698 | 252,038 | ||||||||||||
| Profit attributable to: | ||||||||||||||||
| Owner of the Company | 20,373 | 48,094 | 56,355 | 165,501 | ||||||||||||
| Non-controlling interest | 4,090 | 4,847 | 10,288 | 9,425 | ||||||||||||
| 24,463 | 52,941 | 66,643 | 174,926 | |||||||||||||
| Total comprehensive income attributable to: | ||||||||||||||||
| Owner of the Company | 51,464 | 79,791 | 305,228 | 240,315 | ||||||||||||
| Non-controlling interest | 11,446 | 4,625 | 38,470 | 11,723 | ||||||||||||
| 62,910 | 84,416 | 343,698 | 252,038 | |||||||||||||
| Earnings per share | ||||||||||||||||
| Basic earnings per share | 0.28 | 0.65 | 0.76 | 2.24 | ||||||||||||
| Diluted earnings per share | 0.27 | 0.65 | 0.76 | 2.23 | ||||||||||||
2
| Auna S.A. and Subsidiaries |
| Condensed Consolidated Interim Statement of Changes in Equity |
| For the nine months ended September 30, 2026 and 2025 |
| Equity attributable to the owner of the Company | ||||||||||||||||||||||||||||||||||||||||||||||||
| In thousands of soles | Share capital | Share premium | Other capital reserve | Translation reserve | Cost of reserve | Hedging reserve | Merger and other reserves | Share- based payment reserve | Retained earnings (losses) | Total | Non- controlling interest | Total equity | ||||||||||||||||||||||||||||||||||||
| Balances as of December 31, 2024 | 17,387 | 1,208,586 | 93,012 | (232,770 | ) | 15,392 | (36,494 | ) | 676,491 | 9,145 | (273,533 | ) | 1,477,216 | 145,724 | 1,622,940 | |||||||||||||||||||||||||||||||||
| Balances as of January 1, 2025 | 17,387 | 1,208,586 | 93,012 | (232,770 | ) | 15,392 | (36,494 | ) | 676,491 | 9,145 | (273,533 | ) | 1,477,216 | 145,724 | 1,622,940 | |||||||||||||||||||||||||||||||||
| Profit for the period | — | — | — | — | — | — | — | — | 165,501 | 165,501 | 9,425 | 174,926 | ||||||||||||||||||||||||||||||||||||
| Other comprehensive income for the period | — | — | — | 99,452 | (38,709 | ) | 13,035 | 1,036 | — | — | 74,814 | 2,298 | 77,112 | |||||||||||||||||||||||||||||||||||
| Total comprehensive income for the period | — | — | — | 99,452 | (38,709 | ) | 13,035 | 1,036 | — | 165,501 | 240,315 | 11,723 | 252,038 | |||||||||||||||||||||||||||||||||||
| Issuance of shares | 2 | 1,129 | — | — | — | — | — | (1,131 | ) | — | — | — | — | |||||||||||||||||||||||||||||||||||
| Equity transaction for mandatory purchase of NCI | — | — | — | — | — | — | (68,111 | ) | — | — | (68,111 | ) | — | (68,111 | ) | |||||||||||||||||||||||||||||||||
| Equity-settled share-based payment | — | — | — | — | — | — | — | 8,330 | — | 8,330 | — | 8,330 | ||||||||||||||||||||||||||||||||||||
| Total transactions with the owner of the Company | 2 | 1,129 | — | — | — | — | (68,111 | ) | 7,199 | — | (59,781 | ) | — | (59,781 | ) | |||||||||||||||||||||||||||||||||
| Balances as of September 30, 2025 | 17,389 | 1,209,715 | 93,012 | (133,318 | ) | (23,317 | ) | (23,459 | ) | 609,416 | 16,344 | (108,032 | ) | 1,657,750 | 157,447 | 1,815,197 | ||||||||||||||||||||||||||||||||
| Balances as of December 31, 2025 | 17,389 | 1,209,715 | 109,708 | (148,652 | ) | (21,146 | ) | — | 607,155 | 19,206 | (192,615 | ) | 1,600,760 | 165,596 | 1,766,356 | |||||||||||||||||||||||||||||||||
| Profit for the period | — | — | — | — | — | — | — | — | 56,355 | 56,355 | 10,288 | 66,643 | ||||||||||||||||||||||||||||||||||||
| Other comprehensive income for the period | — | — | — | 238,932 | 21,062 | (10,948 | ) | (173 | ) | — | — | 248,873 | 28,182 | 277,055 | ||||||||||||||||||||||||||||||||||
| Total comprehensive income for the period | — | — | — | 238,932 | 21,062 | (10,948 | ) | (173 | ) | — | 56,355 | 305,228 | 38,470 | 343,698 | ||||||||||||||||||||||||||||||||||
| Issuance of shares | 1 | 1,063 | — | — | — | — | — | (1,064 | ) | — | — | — | — | |||||||||||||||||||||||||||||||||||
| Equity-settled share-based payment | — | — | — | — | — | — | — | 8,559 | — | 8,559 | — | 8,559 | ||||||||||||||||||||||||||||||||||||
| Transfer from legal reserve | — | — | (13,521 | ) | — | — | — | — | — | 13,521 | — | — | — | |||||||||||||||||||||||||||||||||||
| Total transactions with the owner of the Company | 1 | 1,063 | (13,521 | ) | — | — | — | — | 7,495 | 13,521 | 8,559 | — | 8,559 | |||||||||||||||||||||||||||||||||||
| Balances as of September 30, 2026 | 17,390 | 1,210,778 | 96,187 | 90,280 | (84 | ) | (10,948 | ) | 606,982 | 26,701 | (122,739 | ) | 1,914,547 | 204,066 | 2,118,613 | |||||||||||||||||||||||||||||||||
3
| Auna S.A. and Subsidiaries |
| Condensed Consolidated Interim Statement of Cash Flows |
| For the nine months ended September 30, 2026 and 2025 |
| Nine-month period ended September 30 | ||||||||
| In thousands of soles | 2026 | 2025 | ||||||
| Cash flows from operating activities | ||||||||
| Profit for the period | 66,643 | 174,926 | ||||||
| Adjustments for: | ||||||||
| Depreciation | 91,467 | 86,118 | ||||||
| Depreciation of right-of-use assets | 22,178 | 21,321 | ||||||
| Amortization | 63,946 | 58,559 | ||||||
| Impairment of inventories | 609 | 120 | ||||||
| Equity-settled share-based payment transactions | 8,559 | 8,330 | ||||||
| Loss (gain) on disposal of property, furniture, and equipment | 346 | (1,275 | ) | |||||
| Gain on disposal of right-of-use assets net of leases liabilities | — | (9 | ) | |||||
| Impairment of trade receivables | 10,893 | 28,825 | ||||||
| Share of profit of equity-accounted investees | (7,693 | ) | (8,073 | ) | ||||
| Provisions | 4,686 | 1,108 | ||||||
| Finance income | (15,286 | ) | (160,558 | ) | ||||
| Finance costs | 373,803 | 359,232 | ||||||
| Tax expense | 57,662 | 115,622 | ||||||
| Net changes in assets and liabilities: | ||||||||
| Trade accounts receivable and other assets | (72,121 | ) | (132,035 | ) | ||||
| Inventories | 18,704 | (1,443 | ) | |||||
| Trade accounts payable and other accounts payable | 108,724 | 35,230 | ||||||
| Provisions and other reserves | (2,019 | ) | (3,514 | ) | ||||
| Insurance contract liabilities, net | 21,828 | (753 | ) | |||||
| Cash generated from operating activities | 752,929 | 581,731 | ||||||
| Income tax paid | (54,131 | ) | (155,234 | ) | ||||
| Interest received | 13,755 | 13,281 | ||||||
| Net cash from operating activities | 712,553 | 439,778 | ||||||
| Cash flows from investing activities | ||||||||
| Payment for accounts payable to former shareholder | (6,463 | ) | (20,855 | ) | ||||
| Purchase of properties, furniture, and equipment | (70,564 | ) | (66,405 | ) | ||||
| Proceeds from sale of property, furniture, and equipment | 20 | 6,493 | ||||||
| Purchase of intangibles | (40,563 | ) | (46,556 | ) | ||||
| Dividends from equity-accounted investees | 2,196 | 3,169 | ||||||
| Proceeds from sales of other investments, net of purchase | 29,077 | 5,249 | ||||||
| Net cash used in investing activities | (86,297 | ) | (118,905 | ) | ||||
| Cash flows from financing activities | ||||||||
| Proceeds from loans and borrowings | 282,176 | 1,078,860 | ||||||
| Payment for loans and borrowings | (349,190 | ) | (1,084,162 | ) | ||||
| Payment for lease liabilities | (33,521 | ) | (33,516 | ) | ||||
| Penalty paid for debt prepayment | (163 | ) | (81 | ) | ||||
| Payment for derivatives premiums | (14,911 | ) | (16,863 | ) | ||||
| Interest paid | (228,064 | ) | (271,105 | ) | ||||
| Proceeds from settlement of derivatives - interest rate swaps | (19,273 | ) | (9,336 | ) | ||||
| Net cash used in financing activities | (362,946 | ) | (336,203 | ) | ||||
| Net increase (decrease) in cash and cash equivalents | 263,310 | (15,330 | ) | |||||
| Cash and cash equivalents at January 1 | 335,441 | 235,745 | ||||||
| Effect of movements in exchange rates on cash held | 14,876 | 5,295 | ||||||
| Cash and cash equivalents at September 30 | 613,627 | 225,710 | ||||||
| Transactions not representing cash flows | ||||||||
| Assets acquired through finance lease and other financing | 40,062 | 10,493 | ||||||
| Assets acquired from suppliers in installments | 1,230 | 22,163 | ||||||
4
| Auna S.A. and Subsidiaries |
| Notes to the Condensed Consolidated Interim Financial Statements |
| September 30, 2026 |
Operating Segments
| A. | Basis for segmentation |
The Group has determined four reportable segments. These operating segments are components of a company about which separate financial information is available that is regularly evaluated by the Board of Directors (Chief operating decision maker) in deciding how to allocate resources and assess performance.
The following summary describes the operations of each reportable segment.
| Reportable segments | Operations |
| Oncosalud Peru | Including our prepaid oncologic healthcare plans and healthcare services related to the treatment of cancer. |
| Healthcare services in Peru | Corresponds to medical services within the network of clinics and health centers in Peru. |
| Healthcare services in Colombia | Corresponds to medical services within the network of clinics and health centers in Colombia. |
| Healthcare services in Mexico | Corresponds to medical services within the network of clinics and health centers, and the insurance business in Mexico. |
| B. | Information about reportable segments |
Information related to each reportable segment is set out below. Segment profit (loss) before tax is used to measure performance because the chief operating decision maker believes that this information is the most relevant for the Group.
5
| Auna S.A. and Subsidiaries |
| Notes to the Condensed Consolidated Interim Financial Statements |
| September 30, 2026 |
For the three months period ended September 30, 2026:
| Reportable segments | ||||||||||||||||||||||||||||
| In thousands of soles | Oncosalud Peru | Healthcare services in Peru | Healthcare services in Colombia | Healthcare services in Mexico | Total reportable segments | Holding and eliminations | Total | |||||||||||||||||||||
| 2026 | ||||||||||||||||||||||||||||
| External revenues | 308,427 | 207,463 | 493,179 | 315,930 | 1,324,999 | — | 1,324,999 | |||||||||||||||||||||
| Inter-segment revenue (i) | 14,256 | 99,764 | 1,028 | — | 115,048 | (115,048 | ) | — | ||||||||||||||||||||
| Segment revenue | 322,683 | 307,227 | 494,207 | 315,930 | 1,440,047 | (115,048 | ) | 1,324,999 | ||||||||||||||||||||
| External cost of service | (80,587 | ) | (212,520 | ) | (390,991 | ) | (194,824 | ) | (878,922 | ) | — | (878,922 | ) | |||||||||||||||
| Inter-segment cost of service (i) | (103,877 | ) | (14,188 | ) | — | — | (118,065 | ) | 118,065 | — | ||||||||||||||||||
| Segment cost of service | (184,464 | ) | (226,708 | ) | (390,991 | ) | (194,824 | ) | (996,987 | ) | 118,065 | (878,922 | ) | |||||||||||||||
| Gross profit | 138,219 | 80,519 | 103,216 | 121,106 | 443,060 | 3,017 | 446,077 | |||||||||||||||||||||
| External selling expenses | (47,359 | ) | (7,757 | ) | (1,567 | ) | (3,098 | ) | (59,781 | ) | (2,564 | ) | (62,345 | ) | ||||||||||||||
| Segment selling expenses | (47,359 | ) | (7,757 | ) | (1,567 | ) | (3,098 | ) | (59,781 | ) | (2,564 | ) | (62,345 | ) | ||||||||||||||
| External administrative expenses | (20,968 | ) | (32,326 | ) | (68,661 | ) | (70,022 | ) | (191,977 | ) | — | (191,977 | ) | |||||||||||||||
| Inter-segment administrative expenses | (1,123 | ) | (3,183 | ) | — | — | (4,306 | ) | 4,306 | — | ||||||||||||||||||
| Corporate expenses | (17,340 | ) | (14,750 | ) | (3,297 | ) | (3,208 | ) | (38,595 | ) | (1,606 | ) | (40,201 | ) | ||||||||||||||
| Segment administrative expenses | (39,431 | ) | (50,259 | ) | (71,958 | ) | (73,230 | ) | (234,878 | ) | 2,700 | (232,178 | ) | |||||||||||||||
| Impairment losses on trade receivables | (374 | ) | 680 | (3,408 | ) | 257 | (2,845 | ) | — | (2,845 | ) | |||||||||||||||||
| Other income | 474 | 1,822 | 1,075 | 1,758 | 5,129 | 4,377 | 9,506 | |||||||||||||||||||||
| Inter-segment other income | 4,221 | 199 | — | 5,377 | 9,797 | (9,797 | ) | — | ||||||||||||||||||||
| Other income | 4,695 | 2,021 | 1,075 | 7,135 | 14,926 | (5,420 | ) | 9,506 | ||||||||||||||||||||
| Segment operating profit (loss) | 55,750 | 25,204 | 27,358 | 52,170 | 160,482 | (2,267 | ) | 158,215 | ||||||||||||||||||||
| Share of profit of equity accounted investees, net of taxes | 889 | — | 1,790 | — | 2,679 | 1 | 2,680 | |||||||||||||||||||||
| Exchange difference, net | 572 | (270 | ) | 12,830 | 1,079 | 14,211 | (14,125 | ) | 86 | |||||||||||||||||||
| Interest expense, net | (4,403 | ) | (4,039 | ) | (26,653 | ) | (41,999 | ) | (77,094 | ) | (35,146 | ) | (112,240 | ) | ||||||||||||||
| Segment profit (loss) before tax | 52,808 | 20,895 | 15,325 | 11,250 | 100,278 | (51,537 | ) | 48,741 | ||||||||||||||||||||
| Other disclosures | ||||||||||||||||||||||||||||
| Depreciation and amortization | (10,452 | ) | (10,999 | ) | (13,906 | ) | (23,508 | ) | (58,865 | ) | (2,525 | ) | (61,390 | ) | ||||||||||||||
| Capital expenditure | (19,789 | ) | (16,663 | ) | (18,424 | ) | (15,365 | ) | (70,241 | ) | (7,649 | ) | (77,890 | ) | ||||||||||||||
| Segment assets | 49,025 | (29,024 | ) | 140,751 | (68,768 | ) | 91,984 | 59,254 | 151,238 | |||||||||||||||||||
| Segment liabilities | 16,369 | (42,499 | ) | 84,874 | (54,868 | ) | 3,876 | 80,787 | 84,663 | |||||||||||||||||||
6
| Auna S.A. and Subsidiaries |
| Notes to the Condensed Consolidated Interim Financial Statements |
| September 30, 2026 |
For the three months period ended September 30, 2025:
| Reportable segments | ||||||||||||||||||||||||||||
| In thousands of soles | Oncosalud Peru | Healthcare services in Peru | Healthcare services in Colombia | Healthcare services in Mexico | Total reportable segments | Holding and eliminations | Total | |||||||||||||||||||||
| 2025 | ||||||||||||||||||||||||||||
| External revenues | 286,410 | 201,887 | 364,566 | 264,109 | 1,116,972 | — | 1,116,972 | |||||||||||||||||||||
| Inter-segment revenue (i) | 7,287 | 77,203 | 3,957 | — | 88,447 | (88,447 | ) | — | ||||||||||||||||||||
| Segment revenue | 293,697 | 279,090 | 368,523 | 264,109 | 1,205,419 | (88,447 | ) | 1,116,972 | ||||||||||||||||||||
| External cost of service | (83,944 | ) | (185,953 | ) | (275,633 | ) | (152,319 | ) | (697,849 | ) | — | (697,849 | ) | |||||||||||||||
| Inter-segment cost of service (i) | (73,209 | ) | (9,290 | ) | — | — | (82,499 | ) | 82,499 | — | ||||||||||||||||||
| Segment cost of service | (157,153 | ) | (195,243 | ) | (275,633 | ) | (152,319 | ) | (780,348 | ) | 82,499 | (697,849 | ) | |||||||||||||||
| Gross profit | 136,544 | 83,847 | 92,890 | 111,790 | 425,071 | (5,948 | ) | 419,123 | ||||||||||||||||||||
| External selling expenses | (47,813 | ) | (6,140 | ) | (1,245 | ) | (3,892 | ) | (59,090 | ) | (24 | ) | (59,114 | ) | ||||||||||||||
| Segment selling expenses | (47,813 | ) | (6,140 | ) | (1,245 | ) | (3,892 | ) | (59,090 | ) | (24 | ) | (59,114 | ) | ||||||||||||||
| External administrative expenses | (18,545 | ) | (29,996 | ) | (51,212 | ) | (58,424 | ) | (158,177 | ) | — | (158,177 | ) | |||||||||||||||
| Inter-segment administrative expenses | (757 | ) | (2,037 | ) | — | — | (2,794 | ) | 2,794 | — | ||||||||||||||||||
| Corporate expenses | (17,266 | ) | (17,096 | ) | (2,462 | ) | (1,735 | ) | (38,559 | ) | (3,095 | ) | (41,654 | ) | ||||||||||||||
| Segment administrative expenses | (36,568 | ) | (49,129 | ) | (53,674 | ) | (60,159 | ) | (199,530 | ) | (301 | ) | (199,831 | ) | ||||||||||||||
| Impairment losses on trade receivables | (573 | ) | (1,138 | ) | (2,405 | ) | (1,379 | ) | (5,495 | ) | 14 | (5,481 | ) | |||||||||||||||
| Other income | 960 | 1,889 | 1,029 | 7,146 | 11,024 | (106 | ) | 10,918 | ||||||||||||||||||||
| Inter-segment other income | 3,002 | 238 | — | — | 3,240 | (3,240 | ) | — | ||||||||||||||||||||
| Other income | 3,962 | 2,127 | 1,029 | 7,146 | 14,264 | (3,346 | ) | 10,918 | ||||||||||||||||||||
| Segment operating profit (loss) | 55,552 | 29,567 | 36,595 | 53,506 | 175,220 | (9,605 | ) | 165,615 | ||||||||||||||||||||
| Share of profit of equity accounted investees, net of taxes | 782 | — | 2,117 | — | 2,899 | — | 2,899 | |||||||||||||||||||||
| Exchange difference, net | 756 | 483 | 17,255 | 8,471 | 26,965 | 12,721 | 39,686 | |||||||||||||||||||||
| Interest expense, net | (3,397 | ) | (9,838 | ) | (23,032 | ) | (41,453 | ) | (77,720 | ) | (33,741 | ) | (111,461 | ) | ||||||||||||||
| Segment profit (loss) before tax | 53,693 | 20,212 | 32,935 | 20,524 | 127,364 | (30,625 | ) | 96,739 | ||||||||||||||||||||
| Other disclosures | ||||||||||||||||||||||||||||
| Depreciation and amortization | (9,164 | ) | (12,397 | ) | (10,749 | ) | (22,205 | ) | (54,515 | ) | (2,796 | ) | (57,311 | ) | ||||||||||||||
| Capital expenditure | (7,351 | ) | (4,297 | ) | (5,104 | ) | (9,583 | ) | (26,335 | ) | (3,118 | ) | (29,453 | ) | ||||||||||||||
| Segment assets | 95,919 | 41,289 | 80,639 | 46,250 | 264,097 | (149,202 | ) | 114,895 | ||||||||||||||||||||
| Segment liabilities | 64,688 | 30,808 | 103,753 | 34,908 | 234,157 | (138,445 | ) | 95,712 | ||||||||||||||||||||
7
| Auna S.A. and Subsidiaries |
| Notes to the Condensed Consolidated Interim Financial Statements |
| September 30, 2026 |
For the nine months period ended September 30, 2026:
| Reportable segments | ||||||||||||||||||||||||||||
| In thousands of soles | Oncosalud Peru | Healthcare services in Peru | Healthcare services in Colombia | Healthcare services in Mexico | Total reportable segments | Holding and eliminations | Total | |||||||||||||||||||||
| 2026 | ||||||||||||||||||||||||||||
| External revenues | 912,226 | 616,001 | 1,317,500 | 895,022 | 3,740,749 | — | 3,740,749 | |||||||||||||||||||||
| Inter-segment revenue (i) | 41,479 | 268,732 | 3,816 | — | 314,027 | (314,027 | ) | — | ||||||||||||||||||||
| Segment revenue | 953,705 | 884,733 | 1,321,316 | 895,022 | 4,054,776 | (314,027 | ) | 3,740,749 | ||||||||||||||||||||
| External cost of service | (260,115 | ) | (607,753 | ) | (1,019,087 | ) | (534,392 | ) | (2,421,347 | ) | — | (2,421,347 | ) | |||||||||||||||
| Inter-segment cost of service (i) | (269,509 | ) | (39,419 | ) | — | — | (308,928 | ) | 308,928 | — | ||||||||||||||||||
| Segment cost of service | (529,624 | ) | (647,172 | ) | (1,019,087 | ) | (534,392 | ) | (2,730,275 | ) | 308,928 | (2,421,347 | ) | |||||||||||||||
| Gross profit | 424,081 | 237,561 | 302,229 | 360,630 | 1,324,501 | (5,099 | ) | 1,319,402 | ||||||||||||||||||||
| External selling expenses | (151,083 | ) | (20,379 | ) | (4,100 | ) | (9,087 | ) | (184,649 | ) | (1,666 | ) | (186,315 | ) | ||||||||||||||
| Segment selling expenses | (151,083 | ) | (20,379 | ) | (4,100 | ) | (9,087 | ) | (184,649 | ) | (1,666 | ) | (186,315 | ) | ||||||||||||||
| External administrative expenses | (59,578 | ) | (98,462 | ) | (186,536 | ) | (210,034 | ) | (554,610 | ) | — | (554,610 | ) | |||||||||||||||
| Inter-segment administrative expenses | (3,105 | ) | (5,973 | ) | — | — | (9,078 | ) | 9,078 | — | ||||||||||||||||||
| Corporate expenses | (53,950 | ) | (45,813 | ) | (11,353 | ) | (9,563 | ) | (120,679 | ) | (2,603 | ) | (123,282 | ) | ||||||||||||||
| Segment administrative expenses | (116,633 | ) | (150,248 | ) | (197,889 | ) | (219,597 | ) | (684,367 | ) | 6,475 | (677,892 | ) | |||||||||||||||
| Impairment losses on trade receivables | (1,046 | ) | (3,619 | ) | (4,576 | ) | (1,652 | ) | (10,893 | ) | — | (10,893 | ) | |||||||||||||||
| Other income | 1,564 | 5,145 | 6,989 | 17,257 | 30,955 | (128 | ) | 30,827 | ||||||||||||||||||||
| Inter-segment other income | 10,975 | 663 | — | 5,377 | 17,015 | (17,015 | ) | — | ||||||||||||||||||||
| Other income | 12,539 | 5,808 | 6,989 | 22,634 | 47,970 | (17,143 | ) | 30,827 | ||||||||||||||||||||
| Segment operating profit (loss) | 167,858 | 69,123 | 102,653 | 152,928 | 492,562 | (17,433 | ) | 475,129 | ||||||||||||||||||||
| Share of profit of equity accounted investees, net of taxes | 2,485 | — | 5,207 | — | 7,692 | 1 | 7,693 | |||||||||||||||||||||
| Exchange difference, net | (3,044 | ) | (978 | ) | 51,115 | (31 | ) | 47,062 | (65,490 | ) | (18,428 | ) | ||||||||||||||||
| Interest expense, net | (13,470 | ) | (14,235 | ) | (78,527 | ) | (130,510 | ) | (236,742 | ) | (103,347 | ) | (340,089 | ) | ||||||||||||||
| Segment profit (loss) before tax | 153,829 | 53,910 | 80,448 | 22,387 | 310,574 | (186,269 | ) | 124,305 | ||||||||||||||||||||
| Other disclosures | ||||||||||||||||||||||||||||
| Depreciation and amortization | (31,463 | ) | (32,430 | ) | (36,460 | ) | (69,645 | ) | (169,998 | ) | (7,593 | ) | (177,591 | ) | ||||||||||||||
| Capital expenditure | (33,268 | ) | (32,452 | ) | (30,290 | ) | (40,172 | ) | (136,182 | ) | (16,237 | ) | (152,419 | ) | ||||||||||||||
| Segment assets | 2,498,708 | 1,008,909 | 2,951,326 | 3,216,161 | 9,675,104 | (1,728,174 | ) | 7,946,930 | ||||||||||||||||||||
| Segment liabilities | 1,102,755 | 563,229 | 1,613,557 | 1,979,037 | 5,258,578 | 569,739 | 5,828,317 | |||||||||||||||||||||
8
| Auna S.A. and Subsidiaries |
| Notes to the Condensed Consolidated Interim Financial Statements |
| September 30, 2026 |
For the nine months period ended September 30, 2025:
| Reportable segments | ||||||||||||||||||||||||||||
| In thousands of soles | Oncosalud Peru | Healthcare services in Peru | Healthcare services in Colombia | Healthcare services in Mexico | Total reportable segments | Holding and eliminations | Total | |||||||||||||||||||||
| 2025 | ||||||||||||||||||||||||||||
| External revenues | 833,399 | 589,160 | 1,049,582 | 780,638 | 3,252,779 | — | 3,252,779 | |||||||||||||||||||||
| Inter-segment revenue (i) | 27,124 | 222,345 | 3,957 | — | 253,426 | (253,426 | ) | — | ||||||||||||||||||||
| Segment revenue | 860,523 | 811,505 | 1,053,539 | 780,638 | 3,506,205 | (253,426 | ) | 3,252,779 | ||||||||||||||||||||
| External cost of service | (236,766 | ) | (541,383 | ) | (774,499 | ) | (464,989 | ) | (2,017,637 | ) | — | (2,017,637 | ) | |||||||||||||||
| Inter-segment cost of service (i) | (220,437 | ) | (24,475 | ) | — | — | (244,912 | ) | 244,912 | — | ||||||||||||||||||
| Segment cost of service | (457,203 | ) | (565,858 | ) | (774,499 | ) | (464,989 | ) | (2,262,549 | ) | 244,912 | (2,017,637 | ) | |||||||||||||||
| Gross profit | 403,320 | 245,647 | 279,040 | 315,649 | 1,243,656 | (8,514 | ) | 1,235,142 | ||||||||||||||||||||
| External selling expenses | (139,235 | ) | (16,127 | ) | (3,912 | ) | (8,625 | ) | (167,899 | ) | 958 | (166,941 | ) | |||||||||||||||
| Segment selling expenses | (139,235 | ) | (16,127 | ) | (3,912 | ) | (8,625 | ) | (167,899 | ) | 958 | (166,941 | ) | |||||||||||||||
| External administrative expenses | (56,792 | ) | (87,774 | ) | (146,958 | ) | (170,501 | ) | (462,025 | ) | — | (462,025 | ) | |||||||||||||||
| Inter-segment administrative expenses | (3,190 | ) | (5,535 | ) | — | — | (8,725 | ) | 8,725 | — | ||||||||||||||||||
| Corporate expenses | (50,765 | ) | (49,907 | ) | (8,216 | ) | (5,185 | ) | (114,073 | ) | (14,365 | ) | (128,438 | ) | ||||||||||||||
| Segment administrative expenses | (110,747 | ) | (143,216 | ) | (155,174 | ) | (175,686 | ) | (584,823 | ) | (5,640 | ) | (590,463 | ) | ||||||||||||||
| Impairment losses on trade receivables | (1,681 | ) | (10,787 | ) | (14,058 | ) | (2,298 | ) | (28,824 | ) | (1 | ) | (28,825 | ) | ||||||||||||||
| Other income | 2,051 | 4,990 | 6,665 | 18,526 | 32,232 | 4 | 32,236 | |||||||||||||||||||||
| Inter-segment other income | 9,264 | 708 | — | — | 9,972 | (9,972 | ) | — | ||||||||||||||||||||
| Other income | 11,315 | 5,698 | 6,665 | 18,526 | 42,204 | (9,968 | ) | 32,236 | ||||||||||||||||||||
| Segment operating profit (loss) | 162,972 | 81,215 | 112,561 | 147,566 | 504,314 | (23,165 | ) | 481,149 | ||||||||||||||||||||
| Share of profit of equity accounted investees, net of taxes | 2,710 | — | 5,363 | — | 8,073 | — | 8,073 | |||||||||||||||||||||
| Exchange difference, net | 445 | 3,549 | 58,172 | 21,756 | 83,922 | 61,280 | 145,202 | |||||||||||||||||||||
| Interest expense, net | (13,865 | ) | (30,833 | ) | (70,923 | ) | (127,920 | ) | (243,541 | ) | (100,335 | ) | (343,876 | ) | ||||||||||||||
| Segment profit (loss) before tax | 152,262 | 53,931 | 105,173 | 41,402 | 352,768 | (62,220 | ) | 290,548 | ||||||||||||||||||||
| Other disclosures | ||||||||||||||||||||||||||||
| Depreciation and amortization | (26,512 | ) | (35,969 | ) | (30,571 | ) | (64,831 | ) | (157,883 | ) | (8,115 | ) | (165,998 | ) | ||||||||||||||
| Capital expenditure | (16,236 | ) | (28,382 | ) | (12,934 | ) | (36,357 | ) | (93,909 | ) | (7,382 | ) | (101,291 | ) | ||||||||||||||
| Segment assets | 2,400,793 | 1,089,598 | 2,415,418 | 3,168,617 | 9,074,426 | (1,792,404 | ) | 7,282,022 | ||||||||||||||||||||
| Segment liabilities | 1,151,687 | 687,104 | 1,335,685 | 1,925,403 | 5,099,879 | 366,946 | 5,466,825 | |||||||||||||||||||||
9
| Auna S.A. and Subsidiaries |
| Notes to the Condensed Consolidated Interim Financial Statements |
| September 30, 2026 |
| (i) | Inter-segment cost of service (claims expense) from the Oncosalud Peru segment and intersegment revenue from our Healthcare Services in Peru segment are presented on a gross basis by adding the corresponding profit margin markup by our Healthcare Services in Peru segment and vice versa. Likewise, our Oncosalud Peru segment consolidates Oncocenter Peru S.A.C., a subsidiary providing healthcare services related to the exclusive treatment of cancer. In the separate financial statements of Oncocenter Peru S.A.C., the revenue mainly consists of the insurance claims expense recorded as cost of sales in the separate financial statements of Oncosalud S.A.C., our insurance subsidiary that is also consolidated in Oncosalud Peru segment. In the segment consolidation process the related revenues from such healthcare services are eliminated with the corresponding claims expense of our insurance subsidiary Oncosalud S.A.C., while the external cost (third parties) of services incurred by Oncocenter Peru S.A.C. remains. |
10